<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:12:44Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10909525" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10909525</identifier>
        <datestamp>2024-03-04</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="aji13542" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Am J Reprod Immunol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Am J Reprod Immunol</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1600-0897</journal-id>
              <journal-id journal-id-type="publisher-id">AJI</journal-id>
              <journal-title-group>
                <journal-title>American Journal of Reproductive Immunology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1046-7408</issn>
              <issn pub-type="epub">1600-0897</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10909525</article-id>
              <article-id pub-id-type="pmcid">PMC10909525</article-id>
              <article-id pub-id-type="pmc-uid">10909525</article-id>
              <article-id pub-id-type="pmid">35394678</article-id>
              <article-id pub-id-type="pmid">35394678</article-id>
              <article-id pub-id-type="doi">10.1111/aji.13542</article-id>
              <article-id pub-id-type="publisher-id">AJI13542</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Reproductive Immunology</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Genital inflammatory status and the innate immune response to contraceptive initiation</article-title>
                <alt-title alt-title-type="left-running-head">RADZEY et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="aji13542-cr-0001" contrib-type="author">
                  <name>
                    <surname>Radzey</surname>
                    <given-names>Nina</given-names>
                  </name>
                  <xref rid="aji13542-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0002" contrib-type="author">
                  <name>
                    <surname>Harryparsad</surname>
                    <given-names>Rushil</given-names>
                  </name>
                  <xref rid="aji13542-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0003" contrib-type="author">
                  <name>
                    <surname>Meyer</surname>
                    <given-names>Bahiah</given-names>
                  </name>
                  <xref rid="aji13542-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0004" contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Pai Lien</given-names>
                  </name>
                  <xref rid="aji13542-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0005" contrib-type="author">
                  <name>
                    <surname>Gao</surname>
                    <given-names>Xiaoming</given-names>
                  </name>
                  <xref rid="aji13542-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0006" contrib-type="author">
                  <name>
                    <surname>Morrison</surname>
                    <given-names>Charles</given-names>
                  </name>
                  <xref rid="aji13542-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0007" contrib-type="author">
                  <name>
                    <surname>Taku</surname>
                    <given-names>Ongeziwe</given-names>
                  </name>
                  <xref rid="aji13542-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0008" contrib-type="author">
                  <name>
                    <surname>Williamson</surname>
                    <given-names>Anna‐Lise</given-names>
                  </name>
                  <xref rid="aji13542-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0009" contrib-type="author">
                  <name>
                    <surname>Mehou‐Loko</surname>
                    <given-names>Celia</given-names>
                  </name>
                  <xref rid="aji13542-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0010" contrib-type="author">
                  <name>
                    <surname>Lefebvre d'Hellencourt</surname>
                    <given-names>Florence</given-names>
                  </name>
                  <xref rid="aji13542-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0011" contrib-type="author">
                  <name>
                    <surname>Buck</surname>
                    <given-names>Gregory</given-names>
                  </name>
                  <xref rid="aji13542-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0012" contrib-type="author">
                  <name>
                    <surname>Smit</surname>
                    <given-names>Jennifer</given-names>
                  </name>
                  <xref rid="aji13542-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0013" contrib-type="author">
                  <name>
                    <surname>Strauss</surname>
                    <given-names>Jerome</given-names>
                  </name>
                  <xref rid="aji13542-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0014" contrib-type="author">
                  <name>
                    <surname>Nanda</surname>
                    <given-names>Kavita</given-names>
                  </name>
                  <xref rid="aji13542-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0015" contrib-type="author">
                  <name>
                    <surname>Ahmed</surname>
                    <given-names>Khatija</given-names>
                  </name>
                  <xref rid="aji13542-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="aji13542-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0016" contrib-type="author">
                  <name>
                    <surname>Beksinska</surname>
                    <given-names>Mags</given-names>
                  </name>
                  <xref rid="aji13542-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0017" contrib-type="author">
                  <name>
                    <surname>Serrano</surname>
                    <given-names>Myrna</given-names>
                  </name>
                  <xref rid="aji13542-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0018" contrib-type="author">
                  <name>
                    <surname>Bailey</surname>
                    <given-names>Veronique</given-names>
                  </name>
                  <xref rid="aji13542-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="aji13542-cr-0019" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Masson</surname>
                    <given-names>Lindi</given-names>
                  </name>
                  <xref rid="aji13542-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aji13542-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                  <xref rid="aji13542-aff-0008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                  <xref rid="aji13542-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <address>
                    <email>lindi.masson@burnet.edu.au</email>
                  </address>
                </contrib>
                <contrib id="aji13542-cr-0020" contrib-type="author">
                  <name>
                    <surname>Deese</surname>
                    <given-names>Jennifer</given-names>
                  </name>
                  <xref rid="aji13542-aff-0010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aji13542-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Institute of Infectious Disease and Molecular Medicine (IDM)</named-content>
                <institution>University of Cape Town</institution>
                <city>Cape Town</city>
                <country country="ZA">South Africa</country>
              </aff>
              <aff id="aji13542-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>FHI 360</institution>
                <city>Durham</city>
                <named-content content-type="country-part">North Carolina</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="aji13542-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <institution>Virginia Commonwealth University</institution>
                <city>Richmond</city>
                <named-content content-type="country-part">Virginia</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="aji13542-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">MatCH Research Unit (MRU), Department of Obstetrics and Gynaecology</named-content>
                <institution>University of the Witwatersrand</institution>
                <city>Durban</city>
                <country country="ZA">South Africa</country>
              </aff>
              <aff id="aji13542-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <institution>Setshaba Research Centre</institution>
                <city>Tshwane</city>
                <country country="ZA">South Africa</country>
              </aff>
              <aff id="aji13542-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medical Microbiology</named-content>
                <institution>University of Pretoria</institution>
                <city>Pretoria</city>
                <country country="ZA">South Africa</country>
              </aff>
              <aff id="aji13542-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Disease Elimination Program, Life Sciences Discipline</named-content>
                <institution>Burnet Institute</institution>
                <city>Melbourne</city>
                <country country="AU">Australia</country>
              </aff>
              <aff id="aji13542-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <institution>Centre for the AIDS Programme of Research in South Africa</institution>
                <city>Durban</city>
                <country country="ZA">South Africa</country>
              </aff>
              <aff id="aji13542-aff-0009">
                <label>
                  <sup>9</sup>
                </label>
                <named-content content-type="organisation-division">Central Clinical School</named-content>
                <institution>Monash University</institution>
                <city>Melbourne</city>
                <country country="AU">Australia</country>
              </aff>
              <aff id="aji13542-aff-0010">
                <label>
                  <sup>10</sup>
                </label>
                <institution>RTI International</institution>
                <city>Research Triangle Park</city>
                <named-content content-type="country-part">North Carolina</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Lindi Masson, Burnet Institute, 85 Commercial Road, Melbourne, VIC 3004, Australia.<break/>Email: <email>lindi.masson@burnet.edu.au</email><break/></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>8</month>
                <year>2022</year>
              </pub-date>
              <volume>88</volume>
              <issue seq="90">2</issue>
              <issue-id pub-id-type="doi">10.1111/aji.v88.2</issue-id>
              <elocation-id>e13542</elocation-id>
              <history>
                <date date-type="rev-recd">
                  <day>14</day>
                  <month>3</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>01</day>
                  <month>12</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>21</day>
                  <month>3</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">American Journal of Reproductive Immunology</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:AJI-88-e13542.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="aji13542-sec-0010">
                  <title>Problem</title>
                  <p>Data on the effects of contraceptives on female genital tract (FGT) immune mediators are inconsistent, possibly in part due to pre‐existing conditions that influence immune mediator changes in response to contraceptive initiation.</p>
                </sec>
                <sec id="aji13542-sec-0020">
                  <title>Methods</title>
                  <p>This study included 161 South African women randomised to injectable depot medroxyprogesterone acetate (DMPA‐IM), copper intrauterine device (IUD), or levonorgestrel (LNG) implant in the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial. We measured thirteen cytokines and antimicrobial peptides previously associated with HIV acquisition in vaginal swabs using Luminex and ELISA, before, and at 1 and 3 months after contraceptive initiation. Women were grouped according to an overall baseline inflammatory profile. We evaluated modification of the relationships between contraceptives and immune mediators by baseline inflammation, demographic, and clinical factors.</p>
                </sec>
                <sec id="aji13542-sec-0030">
                  <title>Results</title>
                  <p>Overall, LNG implant and copper IUD initiation were associated with increases in inflammatory cytokines, while no changes were observed following DMPA‐IM initiation. However, when stratifying by baseline inflammatory profile, women with low baseline inflammation in all groups experienced significant increases in inflammatory cytokines, while those with a high baseline inflammatory profile experienced no change or decreases in inflammatory cytokines.</p>
                </sec>
                <sec id="aji13542-sec-0040">
                  <title>Conclusion</title>
                  <p>We conclude that pre‐contraceptive initiation immune profile modifies the effect of contraceptives on the FGT innate immune response.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="aji13542-kwd-0001">contraception</kwd>
                <kwd id="aji13542-kwd-0002">copper</kwd>
                <kwd id="aji13542-kwd-0003">cytokines</kwd>
                <kwd id="aji13542-kwd-0004">female</kwd>
                <kwd id="aji13542-kwd-0005">inflammation</kwd>
                <kwd id="aji13542-kwd-0006">intrauterine devices</kwd>
                <kwd id="aji13542-kwd-0007">levonorgestrel</kwd>
                <kwd id="aji13542-kwd-0008">medroxyprogesterone acetate</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>National Institute of Health</funding-source>
                  <award-id>R01HD096937‐01</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>Carnegie Corporation of New York
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000308</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Research Foundation
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100001321</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>
                    <institution-wrap>
                      <institution>Bill &amp; Melinda Gates Foundation
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000865</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>OPP1032115</award-id>
                </award-group>
                <award-group id="funding-0005">
                  <funding-source>
                    <institution-wrap>
                      <institution>United States Agency for International Development
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000200</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>AID‐OAA‐A‐15‐00045</award-id>
                </award-group>
                <award-group id="funding-0006">
                  <funding-source>
                    <institution-wrap>
                      <institution>Swedish International Development Cooperation Agency
</institution>
                      <institution-id institution-id-type="doi">10.13039/100004441</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>2017/762965‐0</award-id>
                </award-group>
                <award-group id="funding-0007">
                  <funding-source>South Africa Medical Research Council</funding-source>
                </award-group>
                <award-group id="funding-0008">
                  <funding-source>
                    <institution-wrap>
                      <institution>United Nations Population Fund
</institution>
                      <institution-id institution-id-type="doi">10.13039/100006661</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0009">
                  <funding-source>Government of South Africa and US Agency for International Development</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="6"/>
                <table-count count="2"/>
                <page-count count="16"/>
                <word-count count="8009"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>August 2022</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.8 mode:remove_FC converted:03.03.2024</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="aji13542-cit-0065"><string-name><surname>Radzey</surname><given-names>N</given-names></string-name>, <string-name><surname>Harryparsad</surname><given-names>R</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>B</given-names></string-name>, et al. <article-title>Genital inflammatory status and the innate immune response to contraceptive initiation</article-title>. <source>Am J Reprod Immunol</source>. <year>2022</year>;<volume>88</volume>:<elocation-id>e13542</elocation-id>. <pub-id pub-id-type="doi">10.1111/aji.13542</pub-id>
<pub-id pub-id-type="pmid">35394678</pub-id>
</mixed-citation>
              </p>
              <fn-group>
                <fn id="aji13542-note-0001">
                  <p>Nina Radzey, Rushil Harryparsad, Bahiah Meyer, Lindi Masson, and Jennifer Deese contributed equally.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body>
            <sec id="aji13542-sec-0050">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Contraceptive use is critical to reduce maternal and infant mortality and morbidity<xref rid="aji13542-bib-0001" ref-type="bibr"><sup>1</sup></xref> and to empower women. Injectables and implants are widely used methods of contraception and account for over half of all modern contraceptive use in Sub‐Saharan Africa.<xref rid="aji13542-bib-0002" ref-type="bibr"><sup>2</sup></xref> The use of hormonal contraceptive methods, particularly the 3‐month 150 mg depot medroxyprogesterone acetate intramuscular injection (DMPA‐IM), overlaps with high rates of HIV and other sexually transmitted infections (STIs) among young women in Sub‐Saharan Africa.<xref rid="aji13542-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="aji13542-bib-0004" ref-type="bibr"><sup>4</sup></xref> Some observational studies had suggested that DMPA‐IM was associated with up to 40–50% increased risk of HIV,<xref rid="aji13542-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="aji13542-bib-0005" ref-type="bibr"><sup>5</sup></xref> but the Evidence for Contraceptive Options and HIV Outcomes (ECHO) randomized clinical trial found no statistically significant overall differences in HIV acquisition between women using DMPA‐IM, copper IUD or LNG implant.<xref rid="aji13542-bib-0006" ref-type="bibr"><sup>6</sup></xref> However, the study was powered to detect ≥ 50% difference in HIV acquisition between randomized groups and the trial design precluded the ability to provide information on differences in HIV risk between the randomized methods and no method or condom use only.<xref rid="aji13542-bib-0007" ref-type="bibr"><sup>7</sup></xref> It therefore remains unknown whether these contraceptives increase HIV risk relative to other forms of contraception or no contraception. Ultimately, the impact of contraceptives on female genital tract (FGT) immunology in ways that may increase the risk of STIs, including HIV, is not well understood.</p>
              <p>Although FGT inflammation is critical for defence against pathogens, women with increased immune mediators have been shown to have higher risk of STI and HIV acquisition,<xref rid="aji13542-bib-0008" ref-type="bibr"><sup>8</sup></xref> likely due to reduced epithelial barrier integrity and recruitment and activation of HIV target cells. Additionally, sustained reproductive tract inflammation may be associated with infertility, endometriosis and increased risk of preterm labour.<xref rid="aji13542-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="aji13542-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="aji13542-bib-0011" ref-type="bibr"><sup>11</sup></xref>
</p>
              <p>Different contraceptives appear to affect FGT inflammatory profiles in unique ways and published data are inconsistent for injectables,<xref rid="aji13542-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="aji13542-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="aji13542-bib-0014" ref-type="bibr"><sup>14</sup></xref> with some studies demonstrating elevated inflammatory cytokines, while others show decreases or no differences among DMPA‐IM users and control groups. Changes in inflammatory profiles remain largely unexplored for long‐acting reversible contraceptive (LARC) methods, such as LNG implants and copper IUDs. However, use of copper IUDs has been associated with increased bacterial vaginosis (BV),<xref rid="aji13542-bib-0015" ref-type="bibr"><sup>15</sup></xref> a known cause of FGT inflammation.<xref rid="aji13542-bib-0016" ref-type="bibr"><sup>16</sup></xref>
</p>
              <p>A recent study found DMPA‐IM to be associated with increased molecular pathways of inflammation in the vaginal mucosa of <italic toggle="yes">Lactobacillus</italic>‐dominant women, while no differences were seen in non‐<italic toggle="yes">Lactobacillus</italic> dominant women.<xref rid="aji13542-bib-0017" ref-type="bibr"><sup>17</sup></xref> This suggests that pre‐existing differences in FGT immune factors may modify the biological effects of contraceptives and thus may explain discrepant results reported in prior studies.</p>
              <p>The aims of this study were to evaluate changes in immune mediators among 161 South African women following randomization to DMPA‐IM, copper IUD, and LNG implant, and to determine the influence of demographic and biological factors on these changes.</p>
            </sec>
            <sec id="aji13542-sec-0060">
              <label>2</label>
              <title>METHODS</title>
              <sec id="aji13542-sec-0070">
                <label>2.1</label>
                <title>Study participants</title>
                <p>The Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial was a randomised multi‐centre trial conducted in 12 research sites in South Africa, Kenya, Zambia and `Eswatini. Participants were enrolled between December 2015 and September 2017. In brief, women who were not pregnant, HIV‐seronegative, aged 16–35 years, seeking effective contraception, without medical contraindications to the trial contraceptive methods, reported not using injectable, intrauterine or implantable contraception for the previous 6 months and reported being sexually active, were eligible. The study design and primary results have been reported previously.<xref rid="aji13542-bib-0006" ref-type="bibr"><sup>6</sup></xref> Participants at two ECHO trial sites, Setshaba Research Centre (SRC) in Tshwane (<italic toggle="yes">n</italic> = 52) and MatCH Research Unit (MRU) in eThekwini (<italic toggle="yes">n</italic> = 109), South Africa, were invited to participate in a biological mechanisms sub‐study. The University of the Witwatersrand and University of Cape Town Human Research Ethics Committees approved this study and all participants provided written informed consent. Approximately equal numbers of women in each group agreed to specimen collection including 51 in the copper IUD group, 52 in the DMPA‐IM group, and 58 in the LNG implant group for a total of 161 participants. Demographic, behavioural, and clinical data were collected on standardized case report forms in the parent ECHO trial. Cervical ectopy was estimated by clinicians using unaided visual inspection during speculum examination and rated in the following categories: 0–25%, 26–50%, 51–75% and 76–100%.</p>
                <sec id="aji13542-sec-0080">
                  <label>2.1.1</label>
                  <title>Specimen collection</title>
                  <p>Lateral vaginal wall swab samples were collected between June and December 2017 for cytokine, secretory leukocyte protease inhibitor (SLPI), human beta‐defensin (HBD)‐1 and –2, prostate specific antigen (PSA) measurement and STI testing. Specimens were collected at baseline (immediately before contraceptive method initiation), month 1 (M1), and month 3 (M3) for immune marker assessment at near peak (M1) and near trough (M3, before DMPA re‐administration) MPA concentrations. All samples were collected by placing Dacron swabs on the lateral vaginal wall and rotating 360 degrees. Swabs for immune mediator analysis were stored in cryovials at ‐80°C for a median time of 23 months (range: 19–26 months) before further processing and testing.</p>
                </sec>
                <sec id="aji13542-sec-0090">
                  <label>2.1.2</label>
                  <title>Lateral vaginal wall swab processing</title>
                  <p>Frozen lateral vaginal wall swabs were thawed on ice overnight at 4⁰C. The following day, 1 ml of phosphate buffered saline (PBS; Sigma‐Aldrich, P5493) was added to each tube; tubes were vortexed for 60 s at a low speed and subsequently incubated at 4⁰C for 1 h. Excess mucus was scraped off on the inner wall of the tubes and each tube was vortexed for another 30 s at a low speed. Prior to immune marker measurements, the supernatants were transferred into filter centrifuge tubes (Corning® Costar® Spin‐X® tubes Sigma‐Aldrich, CLS8160) and centrifuged for 10 min at 4000 Relative Centrifugal Force (RCF). Filters were removed and the supernatants vortexed for 10 s at a low speed. The tubes were kept on dry ice throughout processing.</p>
                </sec>
                <sec id="aji13542-sec-0100">
                  <label>2.1.3</label>
                  <title>Cytokine, antimicrobial peptide and prostate specific antigen measurement</title>
                  <p>Macrophage inflammatory protein (MIP)‐1α (CCL3), MIP‐1β (CCL4), MIP‐3α (CCL20), interferon gamma‐induced protein (IP)‐10 (CXCL10), regulated on activation, normal T cell expressed and secreted (RANTES; CCL5), interleukin (IL)‐6, IL‐8, IL‐1β and tumour necrosis factor (TNF)‐α, interferon (IFN)‐α, and SLPI were measured using a customized Human Magnetic Luminex Screening Assays (R&amp;D Systems, Minneapolis, USA. Lot L128368, Catalogue number: LXSAHM‐02; LXSAHM‐09). Each of the selected mediators has previously been found to be associated with changes in HIV and/or SIV infection risk.<xref rid="aji13542-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="aji13542-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="aji13542-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="aji13542-bib-0019" ref-type="bibr"><sup>19</sup></xref> Participant samples were randomly assigned to plates and cytokines were measured in duplicate with means used for statistical analysis. All timepoints from the same participants were run on the same plates. Data were generated using a Bio‐Rad Bio‐Plex® 200 system with Bio‐Plex Manager Software 6.1 (Bio‐Rad, Hercules, CA) as described previously.<xref rid="aji13542-bib-0008" ref-type="bibr"><sup>8</sup></xref> Human Defensin Beta 1 and 2 (HBD‐1/2) were measured using Enzyme Linked Immunosorbent Assay (ELISA) kits from Novus Biologicals (Product no. NBP2‐67933 and NBP2‐77363, respectively). Reagent preparation and assay procedures were conducted according to the manufacturer's instructions and a 2‐fold sample dilution was used. Samples were analysed on an ELISA plate reader (Spectramax 250) at 450nm. HBD‐1 and 2 were measured singly due to limited sample volume. For all immune mediators, concentrations that were below the assay lower limit of detection were reported as the mid‐point between the lowest concentration measured and zero. PSA, as a measure of recent unprotected vaginal sex, was measured using Human Kallikrein 3/PSA Quantikine ELISA (R&amp;D Systems, USA).</p>
                </sec>
                <sec id="aji13542-sec-0110">
                  <label>2.1.4</label>
                  <title>STI testing</title>
                  <p>Lateral vaginal wall swab samples were thawed overnight on ice at 4°C. The following day, swabs were eluted in 1 ml phosphate buffered saline (PBS) and 250μl of sample was transferred to labelled sample tubes. DNA was extracted using the Roche Nucleic acid Kit 1 (Cat. No. 03730964001) and the MagNa Pure Compact Instrument (Product no. 03731146001) and 100μl of the extracted DNA was stored at ‐20°C until testing. STI testing was conducted using the STD Direct Flow Chip Kit (Master Diagnostica®–Ref: MAD‐003938M‐HS12). The extracted DNA samples were thawed on ice until fully resuspended. DNA was amplified using multiplex PCR followed by hybridisation according to the manufacturer's instructions for the detection of multiple STI causing organisms including <italic toggle="yes">Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium</italic> and <italic toggle="yes">hominis, Ureaplasma urealyticum/parvum</italic>, Herpes Simplex Virus (HSV)‐1 and 2 and <italic toggle="yes">Treponema pallidum</italic>. The results were analysed using hybriSoft analysis software (Master Diagnostica®). HSV‐2 serology was conducted at Bio Analytical Research Corporation South Africa (BARC SA).<xref rid="aji13542-bib-0006" ref-type="bibr"><sup>6</sup></xref> Vaginal swabs were also examined for the presence of <italic toggle="yes">T. vaginalis</italic> as described by Schirm <italic toggle="yes">et</italic> <italic toggle="yes">al</italic>.<xref rid="aji13542-bib-0020" ref-type="bibr"><sup>20</sup></xref> In brief, primers and JOE‐labelled probe targeting <italic toggle="yes">T. vaginalis</italic>‐specific 2‐kb repeated sequence was employed using ViiA 7 Real‐Time PCR System (ThermoFisher Scientific). All samples were processed in duplicate to determine the mean cycle threshold (Ct) value. Samples with Ct values of less than 40 were considered positive. Wells with no DNA served as no template controls, and standard curves using serial dilutions of <italic toggle="yes">T. vaginalis</italic> genomic DNA were included.</p>
                </sec>
                <sec id="aji13542-sec-0120">
                  <label>2.1.5</label>
                  <title>Data analysis</title>
                  <p>Statistical analyses were performed using STATA (Statacorp, USA), GraphPad Prism (GraphPad Software, USA) and SAS (SAS Institute Inc., USA). Immune mediators with Spearman rho score &lt;.8 for duplicate measures (MIP‐1ß) and those that were undetectable in ≥40% of samples (MIP‐1ß and RANTES) were excluded from analysis (Table <xref rid="aji13542-supitem-0001" ref-type="supplementary-material">S1</xref>). A composite inflammation variable was generated using factor analysis of pro‐inflammatory cytokines (TNF‐α, IL‐6 and IL‐1β) and chemokines (IL‐8, MIP‐1α, IP‐10, MIP‐3α) to group women according to baseline inflammation. Women with factor scores greater than or equal to the median were categorized as high inflammation; those with factors scores below the median were categorized as low inflammation. Immune mediator concentration changes from baseline to M1 and M3 within each contraceptive group and within group stratified by baseline inflammatory profile, were analysed using Wilcoxon signed rank test and Mann‐Whitney U test, respectively. Differences in fold changes between the contraceptive methods at M1 and M3 post contraceptive initiation were assessed using Mann‐Whitney U test. <italic toggle="yes">P</italic>‐values were adjusted for multiple comparisons using a false discovery rate (FDR) step down procedure.<xref rid="aji13542-bib-0021" ref-type="bibr"><sup>21</sup></xref> For multivariable analyses, immune mediator concentrations were transformed using Box‐cox power transformation and analysed using generalized linear models. All analyses were stratified by baseline inflammatory profile; site and age were included as covariates in all models. In addition, baseline demographic and clinical variables including body mass index (BMI, &gt;30 vs. ≤30), PSA (detected/not detected), clinical STI signs (yes/no where yes included vaginal or cervical ulcer or discharge, or cervical motion tenderness), cervical ectopy (yes/no), active STI (positive/negative for any of <italic toggle="yes">C. trachomatis</italic>, <italic toggle="yes">M. genitalium</italic>, <italic toggle="yes">N. gonorrhoeae</italic>, <italic toggle="yes">T. vaginalis</italic> and HSV‐2) and HSV‐2 serostatus (positive/negative) were evaluated as potential effect modifiers in all models; subsequent analyses were stratified for variables with interaction terms with <italic toggle="yes">P</italic>‐values &lt;.1. Confounders were identified from models evaluating immune mediator changes from baseline to M3; variables were evaluated through forward selection and retained if their inclusion resulted in a &gt;10% change in the effect estimate (Table <xref rid="aji13542-supitem-0001" ref-type="supplementary-material">S2</xref>).</p>
                </sec>
              </sec>
            </sec>
            <sec id="aji13542-sec-0130">
              <label>3</label>
              <title>RESULTS</title>
              <p>Demographic and behavioural characteristics were balanced across randomized contraceptive groups at baseline (Table <xref rid="aji13542-tbl-0001" ref-type="table">1</xref>). Refusal rates were low, supporting the idea that women did not self‐select based on any potential confounding variable. Generally, baseline FGT immune mediator concentrations were higher in women aged 15–24 years (<italic toggle="yes">n</italic> = 101) compared to women ≥25 years (<italic toggle="yes">n</italic> = 60), except for HBD‐1 (Table <xref rid="aji13542-supitem-0001" ref-type="supplementary-material">S3</xref>). Six of eleven immune mediators included in this analysis, namely, TNF‐α (<italic toggle="yes">P</italic> = .044), IL‐6 (<italic toggle="yes">P</italic> = .015), IL‐1β (<italic toggle="yes">P</italic> = .001), IL‐8 (<italic toggle="yes">P</italic> = .004), MIP‐1α (<italic toggle="yes">P</italic> = .017) and SLPI (<italic toggle="yes">P</italic> = .034) were statistically significantly higher in younger women. Additionally, concentrations of IL‐1β (<italic toggle="yes">P</italic> = .019) and IL‐8 (<italic toggle="yes">P</italic> = .028) were significantly higher in women with an active STI at baseline compared to women who did not have an STI, and HBD‐2 (<italic toggle="yes">P</italic> = .048) concentrations were lower in women who were HSV‐2 seropositive. Women enrolled at the SRC site in Tshwane had higher concentrations of IL‐6 (<italic toggle="yes">P</italic> = .003) and MIP‐3α (<italic toggle="yes">P</italic> = .039) at baseline compared to women enrolled at the MRU site in eThekwini (Table <xref rid="aji13542-supitem-0001" ref-type="supplementary-material">S3</xref>).</p>
              <table-wrap position="float" id="aji13542-tbl-0001" content-type="TABLE">
                <label>TABLE 1</label>
                <caption>
                  <p>Baseline demographic, behavioural and clinical characteristics of study participants randomized by contraceptive method</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col align="left" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="left" span="1"/>
                  <thead>
                    <tr>
                      <th align="left" rowspan="1" colspan="1"/>
                      <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1">Copper IUD (<italic toggle="yes">n</italic>=51)</th>
                      <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1">DMPA‐IM (<italic toggle="yes">n</italic>=52)</th>
                      <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1">LNG Implant (<italic toggle="yes">n</italic>=58)</th>
                      <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1">Total (<italic toggle="yes">n</italic>=161)</th>
                      <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1"><italic toggle="yes">P</italic>‐value</th>
                    </tr>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" rowspan="1" colspan="1"/>
                      <th align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th>
                      <th align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th>
                      <th align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th>
                      <th align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th>
                      <th align="left" rowspan="1" colspan="1"/>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td colspan="6" align="left" rowspan="1">Site</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Setshaba Research Centre (<italic toggle="yes">n</italic>=52)</td>
                      <td align="left" rowspan="1" colspan="1">17</td>
                      <td align="left" rowspan="1" colspan="1">15</td>
                      <td align="left" rowspan="1" colspan="1">20</td>
                      <td align="left" rowspan="1" colspan="1">52</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">MatCH Research Unit (<italic toggle="yes">n</italic>=109)</td>
                      <td align="left" rowspan="1" colspan="1">34</td>
                      <td align="left" rowspan="1" colspan="1">37</td>
                      <td align="left" rowspan="1" colspan="1">38</td>
                      <td align="left" rowspan="1" colspan="1">109</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td colspan="6" align="left" rowspan="1">Age (in years)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Median (range)</td>
                      <td align="char" rowspan="1" colspan="1">23 (18–33)</td>
                      <td align="char" rowspan="1" colspan="1">23 (18–33)</td>
                      <td align="char" rowspan="1" colspan="1">23 (18–33)</td>
                      <td align="char" rowspan="1" colspan="1">23 (18–33)</td>
                      <td align="left" rowspan="1" colspan="1">.794</td>
                    </tr>
                    <tr>
                      <td colspan="6" align="left" rowspan="1">Marital status</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Married (monogamous)</td>
                      <td align="char" rowspan="1" colspan="1">0 (0)</td>
                      <td align="char" rowspan="1" colspan="1">0 (0)</td>
                      <td align="char" rowspan="1" colspan="1">1 (2)</td>
                      <td align="char" rowspan="1" colspan="1">1 (1)</td>
                      <td align="left" rowspan="1" colspan="1">.677</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Never married</td>
                      <td align="char" rowspan="1" colspan="1">51 (100)</td>
                      <td align="char" rowspan="1" colspan="1">52 (100)</td>
                      <td align="char" rowspan="1" colspan="1">57 (98)</td>
                      <td align="char" rowspan="1" colspan="1">160 (99)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td colspan="6" align="left" rowspan="1">Highest level of education</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Attended post‐secondary school</td>
                      <td align="char" rowspan="1" colspan="1">14 (28)</td>
                      <td align="char" rowspan="1" colspan="1">12 (23)</td>
                      <td align="char" rowspan="1" colspan="1">10 (17)</td>
                      <td align="char" rowspan="1" colspan="1">36 (22)</td>
                      <td align="left" rowspan="1" colspan="1">.981</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Secondary school, complete</td>
                      <td align="char" rowspan="1" colspan="1">13 (26)</td>
                      <td align="char" rowspan="1" colspan="1">16 (31)</td>
                      <td align="char" rowspan="1" colspan="1">25 (43)</td>
                      <td align="char" rowspan="1" colspan="1">54 (34)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Secondary school, not complete</td>
                      <td align="char" rowspan="1" colspan="1">24 (47)</td>
                      <td align="char" rowspan="1" colspan="1">24 (46)</td>
                      <td align="char" rowspan="1" colspan="1">23 (40)</td>
                      <td align="char" rowspan="1" colspan="1">71 (44)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td colspan="6" align="left" rowspan="1">Perlvic exam assessment</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Abnormal</td>
                      <td align="char" rowspan="1" colspan="1">7 (14)</td>
                      <td align="char" rowspan="1" colspan="1">5 (10)</td>
                      <td align="char" rowspan="1" colspan="1">5 (9)</td>
                      <td align="char" rowspan="1" colspan="1">17 (11)</td>
                      <td align="left" rowspan="1" colspan="1">.424</td>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" rowspan="1" colspan="1">Vaginal discharge</td>
                      <td align="char" rowspan="1" colspan="1">6 (86)</td>
                      <td align="char" rowspan="1" colspan="1">3 (60)</td>
                      <td align="char" rowspan="1" colspan="1">5 (100)</td>
                      <td align="char" rowspan="1" colspan="1">14 (82)</td>
                      <td align="left" rowspan="1" colspan="1">.743</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Mucopurulent cervical discharge</td>
                      <td align="char" rowspan="1" colspan="1">0 (0)</td>
                      <td align="char" rowspan="1" colspan="1">2 (40)</td>
                      <td align="char" rowspan="1" colspan="1">1 (20)</td>
                      <td align="char" rowspan="1" colspan="1">3 (18)</td>
                      <td align="left" rowspan="1" colspan="1">.368</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Other</td>
                      <td align="char" rowspan="1" colspan="1">1 (14)</td>
                      <td align="char" rowspan="1" colspan="1">1 (20)</td>
                      <td align="char" rowspan="1" colspan="1">0 (0)</td>
                      <td align="char" rowspan="1" colspan="1">2 (12)</td>
                      <td align="left" rowspan="1" colspan="1">.669</td>
                    </tr>
                    <tr>
                      <td colspan="6" align="left" rowspan="1">Previous contraceptive use</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">None</td>
                      <td align="char" rowspan="1" colspan="1">2 (34)</td>
                      <td align="char" rowspan="1" colspan="1">0 (0)</td>
                      <td align="char" rowspan="1" colspan="1">1 (2)</td>
                      <td align="char" rowspan="1" colspan="1">3 (2)</td>
                      <td align="left" rowspan="1" colspan="1">.506</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">IUD</td>
                      <td align="char" rowspan="1" colspan="1">0 (0)</td>
                      <td align="char" rowspan="1" colspan="1">0 (0)</td>
                      <td align="char" rowspan="1" colspan="1">0 (0)</td>
                      <td align="char" rowspan="1" colspan="1">0 (0)</td>
                      <td align="left" rowspan="1" colspan="1">N/A</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Implant</td>
                      <td align="char" rowspan="1" colspan="1">2 (4)</td>
                      <td align="char" rowspan="1" colspan="1">2 (4)</td>
                      <td align="char" rowspan="1" colspan="1">2 (3)</td>
                      <td align="char" rowspan="1" colspan="1">6 (4)</td>
                      <td align="left" rowspan="1" colspan="1">1</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">DMPA</td>
                      <td align="char" rowspan="1" colspan="1">30 (59)</td>
                      <td align="char" rowspan="1" colspan="1">26 (50)</td>
                      <td align="char" rowspan="1" colspan="1">32 (55)</td>
                      <td align="char" rowspan="1" colspan="1">88 (55)</td>
                      <td align="left" rowspan="1" colspan="1">.774</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">NET‐En</td>
                      <td align="char" rowspan="1" colspan="1">15 (29)</td>
                      <td align="char" rowspan="1" colspan="1">12 (23)</td>
                      <td align="char" rowspan="1" colspan="1">11 (19)</td>
                      <td align="char" rowspan="1" colspan="1">38 (24)</td>
                      <td align="left" rowspan="1" colspan="1">.217</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Oral contraceptives</td>
                      <td align="char" rowspan="1" colspan="1">5 (10)</td>
                      <td align="char" rowspan="1" colspan="1">2 (4)</td>
                      <td align="char" rowspan="1" colspan="1">3 (5)</td>
                      <td align="char" rowspan="1" colspan="1">10 (6)</td>
                      <td align="left" rowspan="1" colspan="1">.432</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Male/female condoms</td>
                      <td align="char" rowspan="1" colspan="1">35 (69)</td>
                      <td align="char" rowspan="1" colspan="1">35 (67)</td>
                      <td align="char" rowspan="1" colspan="1">38 (66)</td>
                      <td align="char" rowspan="1" colspan="1">108 (67)</td>
                      <td align="left" rowspan="1" colspan="1">.761</td>
                    </tr>
                    <tr>
                      <td colspan="6" align="left" rowspan="1">STI prevalence</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">Neisseria gonorrhoeae</italic>
                      </td>
                      <td align="char" rowspan="1" colspan="1">2 (4)</td>
                      <td align="char" rowspan="1" colspan="1">2 (4)</td>
                      <td align="char" rowspan="1" colspan="1">3 (5)</td>
                      <td align="char" rowspan="1" colspan="1">7 (4)</td>
                      <td align="left" rowspan="1" colspan="1">.929</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">Chlamydia trachomatis</italic>
                      </td>
                      <td align="char" rowspan="1" colspan="1">7 (14)</td>
                      <td align="char" rowspan="1" colspan="1">8 (15)</td>
                      <td align="char" rowspan="1" colspan="1">16 (28)</td>
                      <td align="char" rowspan="1" colspan="1">31 (19)</td>
                      <td align="left" rowspan="1" colspan="1">.131</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">Trichomonas vaginalis</italic>
                      </td>
                      <td align="char" rowspan="1" colspan="1">16 (31)</td>
                      <td align="char" rowspan="1" colspan="1">12 (23)</td>
                      <td align="char" rowspan="1" colspan="1">19 (33)</td>
                      <td align="char" rowspan="1" colspan="1">47 (29)</td>
                      <td align="left" rowspan="1" colspan="1">.495</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">
                        <italic toggle="yes">Mycoplasma genitalium</italic>
                      </td>
                      <td align="char" rowspan="1" colspan="1">1 (2)</td>
                      <td align="char" rowspan="1" colspan="1">2 (4)</td>
                      <td align="char" rowspan="1" colspan="1">4 (7)</td>
                      <td align="char" rowspan="1" colspan="1">7 (4)</td>
                      <td align="left" rowspan="1" colspan="1">.444</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">HSV‐2‐shedding</td>
                      <td align="char" rowspan="1" colspan="1">3 (6)</td>
                      <td align="char" rowspan="1" colspan="1">4 (8)</td>
                      <td align="char" rowspan="1" colspan="1">2 (3)</td>
                      <td align="char" rowspan="1" colspan="1">9 (6)</td>
                      <td align="left" rowspan="1" colspan="1">.624</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" rowspan="1" colspan="1">HSV‐2‐serology</td>
                      <td align="char" rowspan="1" colspan="1">14 (27)</td>
                      <td align="char" rowspan="1" colspan="1">21 (40)</td>
                      <td align="char" rowspan="1" colspan="1">18 (31)</td>
                      <td align="char" rowspan="1" colspan="1">53 (33)</td>
                      <td align="left" rowspan="1" colspan="1">.351</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="aji13542-tbl1-note-0001">
                    <p>Abbreviations: IUD, intrauterine device; DMPA‐IM, 150 mg intramuscular depot medroxyprogesterone acetate; LNG, levonorgestrel; BMI, body mass index; HSV‐2, herpes simplex virus type 2; PSA, prostate specific antigen; N/A, not available.</p>
                  </fn>
                </table-wrap-foot>
                <permissions>
                  <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                </permissions>
              </table-wrap>
              <sec id="aji13542-sec-0140">
                <label>3.1</label>
                <title>Changes in immune mediators following contraceptive initiation</title>
                <sec id="aji13542-sec-0150">
                  <label>3.1.1</label>
                  <title>Copper IUD</title>
                  <p>At M1 following copper IUD insertion, concentrations of IL‐6, IL‐1β, IL‐8, MIP‐1α and IP‐10 were significantly raised from baseline. However, these changes did not remain significant after adjusting for multiple comparisons (Figure <xref rid="aji13542-fig-0001" ref-type="fig">1A</xref>). In multivariable models, concentrations of IL‐6 were significantly increased at M1 but no significant changes were observed at M3 in bivariable or multivariable models (Table <xref rid="aji13542-supitem-0001" ref-type="supplementary-material">S4</xref>).</p>
                  <fig-group position="float" id="aji13542-fig-0001" content-type="FIGURE">
                    <label>FIGURE 1</label>
                    <caption>
                      <p>(A‐K). Changes in genital immune mediator concentrations (pg/ml) over time. Boxplots representing mean immune mediator concentrations at baseline, 1 month (m1) and 3 months (m3) following contraceptive initiation in women using (A), copper IUD (<italic toggle="yes">n</italic> = 51), (B), DMPA‐IM (<italic toggle="yes">n</italic> = 52) and (C), LNG implant (<italic toggle="yes">n</italic> = 58). Error bars indicate the ranges. Each coloured line represents one woman and immune mediator changes over time. The colour of the lines is based on the contraceptive methods used (blue, copper IUD; pink, DMPA‐IM; green, LNG implant). Samples were run in duplicate. Wilcoxon signed rank test was used for comparisons and <italic toggle="yes">P</italic>‐values were adjusted for multiple comparisons using a false discovery rate step‐down procedure. Abbreviations: IUD, intrauterine device; DMPA‐IM, 150 mg intramuscular depot medroxyprogesterone acetate; LNG, levonorgestrel; M1, 1‐month post contraceptive initiation; M3, 3 months post contraceptive initiation; TNF‐α, tumour necrosis factor‐alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP‐10, interferon‐γ inducible protein‐10; IFN‐α, interferon‐alpha, SLPI, secretory leukocyte protease inhibitor; HBD, human beta defensin. * Indicates <italic toggle="yes">P</italic> &lt; .05 after adjusting for multiple comparisons</p>
                    </caption>
                    <fig position="anchor" fig-type="FIGURE" id="d99e1350">
                      <graphic xlink:href="AJI-88-e13542-g006" position="anchor" id="jats-graphic-1"/>
                    </fig>
                    <fig position="anchor" fig-type="FIGURE" id="d99e1352">
                      <graphic xlink:href="AJI-88-e13542-g003" position="anchor" id="jats-graphic-3"/>
                    </fig>
                    <fig position="anchor" fig-type="FIGURE" id="d99e1354">
                      <graphic xlink:href="AJI-88-e13542-g002" position="anchor" id="jats-graphic-5"/>
                    </fig>
                  </fig-group>
                </sec>
                <sec id="aji13542-sec-0160">
                  <label>3.1.2</label>
                  <title>DMPA‐IM</title>
                  <p>No significant changes in immune mediator concentrations were observed following DMPA‐IM initiation in bivariable (Figure <xref rid="aji13542-fig-0001" ref-type="fig">1B</xref>) or multivariable models (Table <xref rid="aji13542-supitem-0001" ref-type="supplementary-material">S4</xref>).</p>
                </sec>
                <sec id="aji13542-sec-0170">
                  <label>3.1.3</label>
                  <title>LNG implant</title>
                  <p>At M1 post‐LNG implant insertion, no statistically significant changes in immune mediator concentrations from baseline were evident (Figure <xref rid="aji13542-fig-0001" ref-type="fig">1C</xref>). However, at M3, TNF‐α, IP‐10, MIP‐3α and SLPI concentrations were significantly increased; MIP‐3α remained increased after adjustment in multivariable models (Table <xref rid="aji13542-supitem-0001" ref-type="supplementary-material">S4</xref>).</p>
                  <p>While LNG implant use was associated with more significant changes in immune mediator concentrations compared to copper IUD use, the overall magnitude of change was greater in copper IUD users (Figure <xref rid="aji13542-supitem-0001" ref-type="supplementary-material">S1</xref>).</p>
                </sec>
              </sec>
              <sec id="aji13542-sec-0180">
                <label>3.2</label>
                <title>Baseline FGT immune profiles modify the effects of contraceptives on immune mediator concentrations</title>
                <p>Baseline inflammation, active STI, body mass index (BMI) and cervical ectopy were identified as significant modifiers of the effects of contraceptives on immune mediator changes in multivariable models. Overall, women with low baseline inflammation experienced greater increases in immune mediator concentrations compared to those with high baseline inflammation (Figure <xref rid="aji13542-fig-0002" ref-type="fig">2</xref>; Table <xref rid="aji13542-tbl-0002" ref-type="table">2</xref>). In contrast, women with high baseline FGT inflammation, experienced minimal changes or decreases in immune mediator concentrations following contraceptive initiation (Figure <xref rid="aji13542-fig-0002" ref-type="fig">2</xref>; Table <xref rid="aji13542-tbl-0002" ref-type="table">2</xref>).</p>
                <fig-group position="float" id="aji13542-fig-0002" content-type="FIGURE">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>(A‐K). Fold changes of genital immune mediator concentrations relative to baseline. Bar graphs representing the fold change of immune mediator concentrations at 1‐month (M1) and 3 months (M3) following contraceptive initiation in women using (A), the copper IUD (<italic toggle="yes">n</italic> = 51), (B), DMPA‐IM (<italic toggle="yes">n</italic> = 52) and (C), the LNG implant (<italic toggle="yes">n</italic> = 58) in women with high (pink) and low (blue) baseline inflammation. Women were grouped into high (pink) and low (blue) baseline inflammation using overall factor scores at baseline. Samples were run in duplicate. The immune mediators TNF‐α, IL‐8, MIP‐1α, IL‐6, IP‐10, IL‐1β and MIP‐3α were included in the factor analysis. All pro‐inflammatory cytokines and chemokines were loaded onto the same factor and scores were generated to represent overall level of inflammation. Error bars indicate the 95% confidence intervals. Mann‐Whitney U test was used for comparisons and <italic toggle="yes">P</italic> values were adjusted for multiple comparisons using a false discovery rate step‐down procedure. Abbreviations: IUD, intrauterine device; DMPA‐IM, 150 mg intramuscular depot medroxyprogesterone acetate; LNG, levonorgestrel; M1, 1‐month post contraceptive initiation; M3, 3 months post contraceptive initiation; TNF‐α, tumour necrosis factor‐alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP‐10, interferon‐γ inducible protein‐10; IFN‐α, interferon‐alpha, SLPI, secretory leukocyte protease inhibitor; HBD, human beta defensin. * Indicates <italic toggle="yes">P</italic> &lt; .05 after adjusting for multiple comparisons</p>
                  </caption>
                  <fig position="anchor" fig-type="FIGURE" id="d99e1420">
                    <graphic xlink:href="AJI-88-e13542-g001" position="anchor" id="jats-graphic-7"/>
                  </fig>
                  <fig position="anchor" fig-type="FIGURE" id="d99e1422">
                    <graphic xlink:href="AJI-88-e13542-g004" position="anchor" id="jats-graphic-9"/>
                  </fig>
                  <fig position="anchor" fig-type="FIGURE" id="d99e1424">
                    <graphic xlink:href="AJI-88-e13542-g007" position="anchor" id="jats-graphic-11"/>
                  </fig>
                </fig-group>
                <table-wrap position="float" id="aji13542-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Changes in immune mediator concentrations from baseline to months 1 and 3 (M1 and M3) by contraceptive method stratified by baseline inflammation and adjusted for selected confounders<xref rid="aji13542-tbl2-note-0007" ref-type="table-fn"><sup>a</sup></xref>
</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1"/>
                        <th style="border-bottom:solid 1px #000000" colspan="2" align="left" rowspan="1">Copper IUD (<italic toggle="yes">n</italic>=51)</th>
                        <th style="border-bottom:solid 1px #000000" colspan="2" align="left" rowspan="1">DMPA‐IM (<italic toggle="yes">n</italic>=52)</th>
                        <th style="border-bottom:solid 1px #000000" colspan="2" align="left" rowspan="1">LNG implant (<italic toggle="yes">n</italic>=58)</th>
                      </tr>
                      <tr>
                        <th align="left" rowspan="1" colspan="1"/>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic>‐value</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic>‐value</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic>‐value</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic>‐value</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic>‐value</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic>‐value</th>
                      </tr>
                      <tr>
                        <th style="border-bottom:solid 1px #000000" colspan="7" align="left" rowspan="1">High baseline inflammation</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Immune mediator</th>
                        <th align="left" rowspan="1" colspan="1">M1</th>
                        <th align="left" rowspan="1" colspan="1">M3</th>
                        <th align="left" rowspan="1" colspan="1">M1</th>
                        <th align="left" rowspan="1" colspan="1">M3</th>
                        <th align="left" rowspan="1" colspan="1">M1</th>
                        <th align="left" rowspan="1" colspan="1">M3</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">TNF‐α</td>
                        <td align="left" rowspan="1" colspan="1">.976</td>
                        <td align="left" rowspan="1" colspan="1">.078</td>
                        <td align="left" rowspan="1" colspan="1">.069</td>
                        <td align="left" rowspan="1" colspan="1">.053</td>
                        <td align="left" rowspan="1" colspan="1">.388</td>
                        <td align="left" rowspan="1" colspan="1">.944</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IL‐6</td>
                        <td align="left" rowspan="1" colspan="1">.251</td>
                        <td align="left" rowspan="1" colspan="1">.428</td>
                        <td align="left" rowspan="1" colspan="1">.310</td>
                        <td align="left" rowspan="1" colspan="1">.366</td>
                        <td align="left" rowspan="1" colspan="1">.177</td>
                        <td align="left" rowspan="1" colspan="1">.259</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IL‐1β</td>
                        <td align="left" rowspan="1" colspan="1">.643</td>
                        <td align="left" rowspan="1" colspan="1">.823</td>
                        <td align="left" rowspan="1" colspan="1">.538</td>
                        <td align="left" rowspan="1" colspan="1">.178</td>
                        <td align="left" rowspan="1" colspan="1">.066</td>
                        <td style="background-color:#CC99FF" align="left" rowspan="1" colspan="1">.022</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IL‐8</td>
                        <td align="left" rowspan="1" colspan="1">.481</td>
                        <td align="left" rowspan="1" colspan="1">.070</td>
                        <td align="left" rowspan="1" colspan="1">.064</td>
                        <td align="left" rowspan="1" colspan="1">.075</td>
                        <td align="left" rowspan="1" colspan="1">.222</td>
                        <td align="left" rowspan="1" colspan="1">0.102</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MIP‐1α</td>
                        <td align="left" rowspan="1" colspan="1">.661</td>
                        <td align="left" rowspan="1" colspan="1">.298</td>
                        <td align="left" rowspan="1" colspan="1">.063</td>
                        <td style="background-color:#CC99FF" align="left" rowspan="1" colspan="1">.032</td>
                        <td align="left" rowspan="1" colspan="1">.184</td>
                        <td align="left" rowspan="1" colspan="1">.067</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IP‐10</td>
                        <td align="left" rowspan="1" colspan="1">.531</td>
                        <td align="left" rowspan="1" colspan="1">.671</td>
                        <td align="left" rowspan="1" colspan="1">.057</td>
                        <td style="background-color:#CC99FF" align="left" rowspan="1" colspan="1">.030</td>
                        <td align="left" rowspan="1" colspan="1">.446</td>
                        <td align="left" rowspan="1" colspan="1">.855</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MIP‐3α</td>
                        <td align="left" rowspan="1" colspan="1">.872</td>
                        <td align="left" rowspan="1" colspan="1">.649</td>
                        <td align="left" rowspan="1" colspan="1">.054</td>
                        <td align="left" rowspan="1" colspan="1">.160</td>
                        <td align="left" rowspan="1" colspan="1">.580</td>
                        <td align="left" rowspan="1" colspan="1">.539</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IFN‐α</td>
                        <td align="left" rowspan="1" colspan="1">.893</td>
                        <td align="left" rowspan="1" colspan="1">.914</td>
                        <td align="left" rowspan="1" colspan="1">.277</td>
                        <td align="left" rowspan="1" colspan="1">.328</td>
                        <td align="left" rowspan="1" colspan="1">.297</td>
                        <td style="background-color:#CC99FF" align="left" rowspan="1" colspan="1">.043</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">SLPI</td>
                        <td align="left" rowspan="1" colspan="1">.901</td>
                        <td align="left" rowspan="1" colspan="1">.252</td>
                        <td style="background-color:#CC99FF" align="left" rowspan="1" colspan="1">.046</td>
                        <td align="left" rowspan="1" colspan="1">.111</td>
                        <td align="left" rowspan="1" colspan="1">.279</td>
                        <td align="left" rowspan="1" colspan="1">.671</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HBD‐1</td>
                        <td align="left" rowspan="1" colspan="1">.074</td>
                        <td align="left" rowspan="1" colspan="1">.156</td>
                        <td align="left" rowspan="1" colspan="1">.810</td>
                        <td align="left" rowspan="1" colspan="1">.282</td>
                        <td align="left" rowspan="1" colspan="1">.705</td>
                        <td align="left" rowspan="1" colspan="1">.421</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HBD‐2</td>
                        <td align="left" rowspan="1" colspan="1">.521</td>
                        <td align="left" rowspan="1" colspan="1">.264</td>
                        <td align="left" rowspan="1" colspan="1">.248</td>
                        <td align="left" rowspan="1" colspan="1">.109</td>
                        <td align="left" rowspan="1" colspan="1">.850</td>
                        <td align="left" rowspan="1" colspan="1">.439</td>
                      </tr>
                    </tbody>
                  </table>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="." span="1"/>
                    <col align="char" char="." span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr>
                        <th style="border-bottom:solid 1px #000000" colspan="7" align="left" rowspan="1">Low baseline inflammation</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Immune mediator</th>
                        <th align="left" rowspan="1" colspan="1">M1</th>
                        <th align="left" rowspan="1" colspan="1">M3</th>
                        <th align="left" rowspan="1" colspan="1">M1</th>
                        <th align="left" rowspan="1" colspan="1">M3</th>
                        <th align="left" rowspan="1" colspan="1">M1</th>
                        <th align="left" rowspan="1" colspan="1">M3</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">TNF‐α</td>
                        <td align="char" rowspan="1" colspan="1">.148</td>
                        <td align="char" rowspan="1" colspan="1">.081</td>
                        <td align="left" rowspan="1" colspan="1">.481</td>
                        <td align="left" rowspan="1" colspan="1">.444</td>
                        <td align="left" rowspan="1" colspan="1">.690</td>
                        <td align="left" rowspan="1" colspan="1">.176</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IL‐6</td>
                        <td style="background-color:#FFFF00" align="char" rowspan="1" colspan="1">&lt;.001</td>
                        <td style="background-color:#FFFF00" align="char" rowspan="1" colspan="1">&lt;.001</td>
                        <td align="left" rowspan="1" colspan="1">.094</td>
                        <td align="left" rowspan="1" colspan="1">.290</td>
                        <td style="background-color:#FFFF00" align="left" rowspan="1" colspan="1">.027</td>
                        <td style="background-color:#FFFF00" align="left" rowspan="1" colspan="1">.039</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IL‐1β</td>
                        <td style="background-color:#FFFF00" align="char" rowspan="1" colspan="1">.017</td>
                        <td style="background-color:#FFFF00" align="char" rowspan="1" colspan="1">.012</td>
                        <td align="left" rowspan="1" colspan="1">.221</td>
                        <td align="left" rowspan="1" colspan="1">.231</td>
                        <td align="left" rowspan="1" colspan="1">.395</td>
                        <td align="left" rowspan="1" colspan="1">.534</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IL‐8</td>
                        <td style="background-color:#FFFF00" align="char" rowspan="1" colspan="1">.010</td>
                        <td style="background-color:#FFFF00" align="char" rowspan="1" colspan="1">&lt;.001</td>
                        <td align="left" rowspan="1" colspan="1">.062</td>
                        <td style="background-color:#FFFF00" align="left" rowspan="1" colspan="1">.014</td>
                        <td align="left" rowspan="1" colspan="1">.176</td>
                        <td style="background-color:#FFFF00" align="left" rowspan="1" colspan="1">.018</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MIP‐1α</td>
                        <td align="char" rowspan="1" colspan="1">.066</td>
                        <td style="background-color:#FFFF00" align="char" rowspan="1" colspan="1">.011</td>
                        <td style="background-color:#FFFF00" align="left" rowspan="1" colspan="1">.006</td>
                        <td style="background-color:#FFFF00" align="left" rowspan="1" colspan="1">.002</td>
                        <td align="left" rowspan="1" colspan="1">.669</td>
                        <td align="left" rowspan="1" colspan="1">.086</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IP‐10</td>
                        <td style="background-color:#FFFF00" align="char" rowspan="1" colspan="1">.018</td>
                        <td style="background-color:#FFFF00" align="char" rowspan="1" colspan="1">.006</td>
                        <td align="left" rowspan="1" colspan="1">.088</td>
                        <td align="left" rowspan="1" colspan="1">.510</td>
                        <td align="left" rowspan="1" colspan="1">.115</td>
                        <td style="background-color:#FFFF00" align="left" rowspan="1" colspan="1">.002</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MIP‐3α</td>
                        <td align="char" rowspan="1" colspan="1">.074</td>
                        <td align="char" rowspan="1" colspan="1">.059</td>
                        <td align="left" rowspan="1" colspan="1">.350</td>
                        <td style="background-color:#FFFF00" align="left" rowspan="1" colspan="1">.011</td>
                        <td align="left" rowspan="1" colspan="1">.996</td>
                        <td style="background-color:#FFFF00" align="left" rowspan="1" colspan="1">.004</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IFN‐α</td>
                        <td align="char" rowspan="1" colspan="1">.181</td>
                        <td align="char" rowspan="1" colspan="1">.978</td>
                        <td align="left" rowspan="1" colspan="1">.346</td>
                        <td align="left" rowspan="1" colspan="1">.508</td>
                        <td align="left" rowspan="1" colspan="1">.796</td>
                        <td align="left" rowspan="1" colspan="1">.512</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">SLPI</td>
                        <td align="char" rowspan="1" colspan="1">.553</td>
                        <td align="char" rowspan="1" colspan="1">.075</td>
                        <td align="left" rowspan="1" colspan="1">.793</td>
                        <td align="left" rowspan="1" colspan="1">.166</td>
                        <td align="left" rowspan="1" colspan="1">.673</td>
                        <td style="background-color:#FFFF00" align="left" rowspan="1" colspan="1">.024</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HBD‐1</td>
                        <td align="char" rowspan="1" colspan="1">.073</td>
                        <td align="char" rowspan="1" colspan="1">.193</td>
                        <td align="left" rowspan="1" colspan="1">.292</td>
                        <td align="left" rowspan="1" colspan="1">.282</td>
                        <td align="left" rowspan="1" colspan="1">.324</td>
                        <td align="left" rowspan="1" colspan="1">.421</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HBD‐2</td>
                        <td align="char" rowspan="1" colspan="1">.188</td>
                        <td align="char" rowspan="1" colspan="1">.960</td>
                        <td align="left" rowspan="1" colspan="1">.559</td>
                        <td align="left" rowspan="1" colspan="1">.457</td>
                        <td align="left" rowspan="1" colspan="1">.827</td>
                        <td align="left" rowspan="1" colspan="1">.760</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="aji13542-tbl2-note-0008">
                      <p><inline-graphic xlink:href="AJI-88-e13542-g008.jpg" xlink:title="InlineGraphics"/>significant decrease</p>
                    </fn>
                    <fn id="aji13542-tbl2-note-0009">
                      <p><inline-graphic xlink:href="AJI-88-e13542-g005.jpg" xlink:title="InlineGraphics"/>significant increase</p>
                    </fn>
                    <fn id="aji13542-tbl2-note-0001">
                      <p>Abbreviations: IUD, intrauterine device; DMPA‐IM, 150 mg intramuscular depot medroxyprogesterone acetate; M1; 1‐month following contraceptive initiation; M3, 3 months following contraceptive initiation; LNG, levonorgestrel; TNF‐α, tumour necrosis factor‐alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP‐10, interferon‐γ inducible protein‐10; IFN‐α, interferon‐alpha.</p>
                    </fn>
                    <fn id="aji13542-tbl2-note-0002">
                      <p><italic toggle="yes">Note</italic>: Participants who didn't receive the study contraceptive to which they were randomized are excluded from analyses.</p>
                    </fn>
                    <fn id="aji13542-tbl2-note-0003">
                      <label>
                        <sup>1</sup>
                      </label>
                      <p>Box‐cox power transformation is applied to each cytokine concentration for analyses.</p>
                    </fn>
                    <fn id="aji13542-tbl2-note-0004">
                      <label>
                        <sup>2</sup>
                      </label>
                      <p><italic toggle="yes">P</italic>‐value is computed from T test after a generalized linear model is fit for each cytokine.</p>
                    </fn>
                    <fn id="aji13542-tbl2-note-0005">
                      <label>
                        <sup>3</sup>
                      </label>
                      <p>If a variable of interest has a significant modification effect on a cytokine (<italic toggle="yes">P</italic>&lt;.1), the model for that cytokine will stratify on the variable and adjusted with site and dichotomous age group.</p>
                    </fn>
                    <fn id="aji13542-tbl2-note-0006">
                      <p>Baseline inflammation is stratified on regardless.</p>
                    </fn>
                    <fn id="aji13542-tbl2-note-0007">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>All the models are always adjusted with study site and dichotomous age group (under 25 or otherwise). The confounders are selected forward into the model as covariates from BMI, PSA, clinical signs, ectopy, active STI, and HSV‐2 seropositivity. Variables with at least 10% contribution to the standardized coefficient will be retained in the model.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                  </permissions>
                </table-wrap>
                <sec id="aji13542-sec-0190">
                  <label>3.2.1</label>
                  <title>Copper IUD</title>
                  <p>In copper IUD users, changes in TNF‐α, IL‐8 and MIP‐1α between baseline and M3 were significantly greater in women with low versus those with high baseline inflammation (Figure <xref rid="aji13542-fig-0002" ref-type="fig">2A</xref>). In multivariable models, IL‐6, IL‐1β, IL‐8, and IP‐10 were significantly raised in women with low baseline inflammation at M1 and M3 relative to baseline. Additionally, MIP‐1α followed the same pattern at M3 only (Table <xref rid="aji13542-tbl-0002" ref-type="table">2</xref>). No significant changes were observed among women who had high baseline inflammation.</p>
                </sec>
                <sec id="aji13542-sec-0200">
                  <label>3.2.2</label>
                  <title>DMPA‐IM</title>
                  <p>In DMPA‐IM users, changes in IL‐8, MIP‐1α and IP‐10 between baseline and M1 were significantly greater in women with low compared to high baseline inflammation (Figure <xref rid="aji13542-fig-0002" ref-type="fig">2B</xref>). TNF‐α, IL‐6, IL‐1β, IL‐8, MIP‐3α and SLPI followed the same pattern at M3 (Figure <xref rid="aji13542-fig-0002" ref-type="fig">2B</xref>). In multivariable models, women with low baseline inflammation experienced significant increases in IL‐8 and MIP‐3α at M3 and in MIP‐1α at both M1 and M3, relative to baseline (Table <xref rid="aji13542-tbl-0002" ref-type="table">2</xref>). In the high baseline inflammation group, significant decreases in MIP‐1α and IP‐10 were observed at M3, and SLPI was significantly decreased at M1 relative to baseline (Table <xref rid="aji13542-tbl-0002" ref-type="table">2</xref>).</p>
                </sec>
                <sec id="aji13542-sec-0210">
                  <label>3.2.3</label>
                  <title>LNG implant</title>
                  <p>In LNG implant users, changes in IL‐1β, IL‐8, MIP‐1α and MIP‐3α between baseline and M3 were significantly greater in women with low compared to high baseline inflammation (Figure <xref rid="aji13542-fig-0002" ref-type="fig">2C</xref>). In multivariable models, women with low baseline inflammation experienced significant increases in IL‐6 at M1 and M3 and in IL‐8, IP‐10, MIP‐3α and SLPI at M3 relative to baseline. In contrast, LNG implant use was associated with decreased IL‐1β and IFN‐α concentrations at M1 and M3 relative to baseline in women with high baseline inflammation (Table <xref rid="aji13542-tbl-0002" ref-type="table">2</xref>).</p>
                </sec>
              </sec>
            </sec>
            <sec id="aji13542-sec-0220">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>In South Africa, adolescent girls and young women are at a high risk of STIs and HIV infection. They also need safe and effective contraceptive methods to prevent unplanned pregnancies and as a tool of empowerment. While highly effective contraceptive methods are critical for improving women's health, their impact on FGT immunity, and consequential effects on STI/HIV risk, have been widely debated. In this study, we assessed the effects of DMPA‐IM, copper IUD and LNG implant on FGT immune mediators among South African women participating in the ECHO clinical trial.</p>
              <p>Overall, LNG implant use was associated with increases in several inflammatory cytokines and SLPI at M3 following contraceptive initiation, while women using the copper IUD had increased IL‐6 at M1, and minimal changes were observed in the DMPA‐IM arm. However, stratification of women according to baseline FGT inflammation revealed opposing effects of these contraceptives on immune mediators, dependent on pre‐existing inflammatory profile. In each group, women with low inflammation status at baseline experienced significant increases in immune mediators by M1 and/or M3, while women with high baseline inflammation experienced no significant changes in the copper IUD group and marginally significant decreases in several immune mediators following contraceptive use in the DMPA‐IM and LNG implant group. These findings suggest that pre‐existing differences in local inflammatory profiles, that may be mediated by genetic or environmental factors, modify the effects of contraceptives on FGT innate immune responses. The mechanisms underlying these changes remain to be determined, however, it is unlikely that STI incidence and/or changes in sexual behaviour explain the findings as our analyses were adjusted for these confounders. Our results offer a possible explanation for the contradictory findings of previous studies investigating FGT cytokine changes among women using injectable contraceptives, with some showing elevated inflammatory profiles and others showing reduced inflammation.<xref rid="aji13542-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="aji13542-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="aji13542-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="aji13542-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="aji13542-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="aji13542-bib-0023" ref-type="bibr"><sup>23</sup></xref> Importantly, each of the immune mediators measured in this study has been previously linked to changes in SIV or HIV infection risk.<xref rid="aji13542-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="aji13542-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="aji13542-bib-0018" ref-type="bibr"><sup>18</sup></xref> Elevated concentrations of inflammatory cytokines in the FGT may reduce mucosal barrier integrity,<xref rid="aji13542-bib-0024" ref-type="bibr"><sup>24</sup></xref> leaving the FGT prone to invasion by pathogenic microorganisms, including HIV and several other STI‐causing agents. FGT inflammation is also associated with recruitment and activation of HIV target cells and direct promotion of HIV replication.<xref rid="aji13542-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="aji13542-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="aji13542-bib-0026" ref-type="bibr"><sup>26</sup></xref>
</p>
              <p>In line with our results, a recent study explored the effects of DMPA‐IM on the activation of HIV cellular targets and, importantly, inflammation in sex workers versus non‐sex workers.<xref rid="aji13542-bib-0027" ref-type="bibr"><sup>27</sup></xref> Involvement in sex work has been associated with an immune tolerance phenotype due to constant exposure of the FGT to antigens. DMPA‐IM use, however, was associated with increased T cell activation and inflammation in sex workers to the same level that the authors observed in non‐sex workers using DMPA‐IM.<xref rid="aji13542-bib-0027" ref-type="bibr"><sup>27</sup></xref> Thus, sex workers who had lower immune activation profiles at baseline experienced greater increases in immune mediators following DMPA‐IM initiation compared to non‐sex workers, which is in line with our study.</p>
              <p>There are several factors that may impact an individual's FGT inflammation status prior to contraceptive initiation. Out of the eleven immune mediators measured in this study, nine were elevated in younger women compared to older women at baseline. Previous studies have reported on the inverse relationship between age and genital inflammation<xref rid="aji13542-bib-0008" ref-type="bibr"><sup>8</sup></xref> but the causes are not well understood. Although STIs were associated with elevated levels of some immune mediators at baseline, STI prevalence did not differ between age groups (data not shown) and BMI, cycle phase, presence of PSA, clinical signs as well as cervical ectopy were not associated with immune mediator levels. Thus, it is unlikely that differences in these factors explain the difference in immune mediator levels observed between age groups. One hypothesis is that the reproductive tract of young women represents a naïve reactive state that is anatomically immature and lacks tolerance to sex and male semen, in turn leading to increased genital inflammation and increased risk for STI and HIV infection. Women from SRC in Tshwane also tended to have higher concentrations of genital immune mediators compared to women from MaTCH in eThekwini prior to contraceptive initiation. The vaginal microbiome is closely linked to genital inflammation<xref rid="aji13542-bib-0028" ref-type="bibr"><sup>28</sup></xref> and the vaginal microbial composition has been found to differ by geographical location.<xref rid="aji13542-bib-0029" ref-type="bibr"><sup>29</sup></xref> A <italic toggle="yes">Lactobacillus</italic>‐dominant FGT microbiome is associated with low levels of inflammation and protection against HIV, while women with non‐<italic toggle="yes">Lactobacillus</italic> dominant microbiota have increased inflammation and HIV risk.<xref rid="aji13542-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="aji13542-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="aji13542-bib-0031" ref-type="bibr"><sup>31</sup></xref>, <xref rid="aji13542-bib-0032" ref-type="bibr"><sup>32</sup></xref> Other environmental factors that may directly or indirectly influence local immune mediator levels include STIs, sexual behaviour patterns, such as the number of partners,<xref rid="aji13542-bib-0033" ref-type="bibr"><sup>33</sup></xref> vaginal insertion and/or hygiene practices,<xref rid="aji13542-bib-0034" ref-type="bibr"><sup>34</sup></xref> cigarette smoking<xref rid="aji13542-bib-0035" ref-type="bibr"><sup>35</sup></xref> and Vitamin D levels.<xref rid="aji13542-bib-0036" ref-type="bibr"><sup>36</sup></xref>
</p>
              <p>Other possible factors affecting immune mediators include pattern recognition receptors (PRRs), such as toll‐like receptors (TLRs) and nucleotide‐binding oligomerization domain or NOD‐like receptors (NLRs) that recognize and bind foreign structures known as pathogen‐associated molecular patterns (PAMPs) that are present on microbial cell surfaces, resulting in the stimulation of a pro‐inflammatory immune response. Mouse models have demonstrated that expression levels of these PRRs have the potential to impact immune responsiveness and overall inflammatory profiles<xref rid="aji13542-bib-0037" ref-type="bibr"><sup>37</sup></xref>. Interestingly, it has also been shown that some TLR genes are cyclically expressed throughout the menstrual cycle, with expression levels highest during the secretory phase<xref rid="aji13542-bib-0038" ref-type="bibr"><sup>38</sup></xref>, <xref rid="aji13542-bib-0039" ref-type="bibr"><sup>39</sup></xref>.</p>
              <p>Host genetics may also play a role, and, although evidence of a possible relationship between host genetics and immune mediator levels in the FGT is scarce, some studies have identified gene polymorphisms that modulate inflammatory response in the FGT.<xref rid="aji13542-bib-0040" ref-type="bibr"><sup>40</sup></xref>, <xref rid="aji13542-bib-0041" ref-type="bibr"><sup>41</sup></xref> For example, polymorphisms in the TLR4 gene (896 A&gt;G polymorphisms) may lead to a subdued inflammatory response to lipopolysaccharide (LPS) from <italic toggle="yes">G. vaginalis</italic> among pregnant women.<xref rid="aji13542-bib-0040" ref-type="bibr"><sup>40</sup></xref> Additionally, a polymorphism in the TNF‐α gene (TNFA‐208G&gt;A) was associated with TNF‐α concentrations in BV positive women.<xref rid="aji13542-bib-0041" ref-type="bibr"><sup>41</sup></xref> It is thus possible that host genetics may modulate immune responses to vaginal pathogens and thus impact genital inflammation.</p>
              <p>Sex steroid hormones are inherently linked to the regulation of microbial populations in the FGT.<xref rid="aji13542-bib-0042" ref-type="bibr"><sup>42</sup></xref> While endogenous oestrogen and its synthetic analogue estradiol have previously been associated with an increased abundance of beneficial <italic toggle="yes">Lactobacillus</italic> species,<xref rid="aji13542-bib-0043" ref-type="bibr"><sup>43</sup></xref> the findings of previous studies on the effects of progestin‐only contraceptives, such as DMPA‐IM, on vaginal microbial communities have been inconsistent.<xref rid="aji13542-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="aji13542-bib-0044" ref-type="bibr"><sup>44</sup></xref>, <xref rid="aji13542-bib-0045" ref-type="bibr"><sup>45</sup></xref>, <xref rid="aji13542-bib-0046" ref-type="bibr"><sup>46</sup></xref>, <xref rid="aji13542-bib-0047" ref-type="bibr"><sup>47</sup></xref>, <xref rid="aji13542-bib-0048" ref-type="bibr"><sup>48</sup></xref>, <xref rid="aji13542-bib-0049" ref-type="bibr"><sup>49</sup></xref>, <xref rid="aji13542-bib-0050" ref-type="bibr"><sup>50</sup></xref> The injectable has also been linked to altered cell‐mediated immune responses, which in turn increase a woman's susceptibility to BV and STIs, including HIV. Recently, it has been demonstrated that effects of DMPA‐IM on genital inflammatory pathways may be modified by the FGT microbiome. In a study by Noël‐Romas <italic toggle="yes">et al</italic>., serum‐MPA levels positively correlated with evidence of inflammation in the vaginal mucosal fluid of women with a <italic toggle="yes">Lactobacillus</italic>‐dominant microbiome, but not in women with a non‐<italic toggle="yes">Lactobacillus</italic> dominant microbiome. Additionally, while women with a <italic toggle="yes">Lactobacillus</italic>‐dominant microbiome using DMPA‐IM had a &gt;3‐fold increased risk of HIV acquisition, increased HIV risk was not observed in women who had a non‐<italic toggle="yes">Lactobacillus</italic> dominant microbiome. Therefore, it is possible that DMPA‐IM only increases inflammatory responses among women who do not already have high levels of inflammation.</p>
              <p>Copper IUD use has been associated with increased microbial diversity and BV,<xref rid="aji13542-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="aji13542-bib-0051" ref-type="bibr"><sup>51</sup></xref> providing a possible explanation for the observed increased inflammation. While the mechanisms underlying the association between copper IUD use and BV are not fully established, the presence of a foreign body in the uterus and vagina may facilitate increased growth of anaerobic bacteria associated with BV.<xref rid="aji13542-bib-0051" ref-type="bibr"><sup>51</sup></xref> Another possible explanation is that copper has been found to have antimicrobial activity<xref rid="aji13542-bib-0052" ref-type="bibr"><sup>52</sup></xref> and may differentially impact different bacterial taxa to favour non‐optimal species. Additionally, copper IUD use is frequently accompanied by a temporary increase in volume and duration of menses.<xref rid="aji13542-bib-0053" ref-type="bibr"><sup>53</sup></xref>, <xref rid="aji13542-bib-0054" ref-type="bibr"><sup>54</sup></xref> It has previously been shown that the relative abundance of <italic toggle="yes">G. vaginalis</italic> and <italic toggle="yes">Lactobacillus</italic> species fluctuate throughout a woman's normal menstrual cycle, with menses associated with increased <italic toggle="yes">G. vaginalis</italic> and decreased <italic toggle="yes">Lactobacillus</italic> species.<xref rid="aji13542-bib-0055" ref-type="bibr"><sup>55</sup></xref> An extension of menses in copper IUD users could possibly result in an environment which facilitates increased growth of <italic toggle="yes">G. vaginalis</italic> which may persist to the point of dysbiosis in some women.<xref rid="aji13542-bib-0055" ref-type="bibr"><sup>55</sup></xref>, <xref rid="aji13542-bib-0056" ref-type="bibr"><sup>56</sup></xref>
</p>
              <p>Reports on the inflammatory potential of the LNG implant are sparse. While its use was associated with increases in several immune mediators in this study, Achilles <italic toggle="yes">et al</italic>. found no changes in cervical or systemic HIV target cell populations, cytokines and soluble mediators in women using the LNG implant for up to 6 months following contraceptive initiation.<xref rid="aji13542-bib-0057" ref-type="bibr"><sup>57</sup></xref>
</p>
              <p>Another progestin‐only implant, the etonogestrel implant, however, has previously been linked to higher levels of CD4+ T cells expressing the HIV co‐receptor CCR5, as well as the soluble lymphocyte activation marker (sCD40L) after 3 months of contraceptive initiation.<xref rid="aji13542-bib-0058" ref-type="bibr"><sup>58</sup></xref> Interestingly, scD40L, among other immune mediators, was associated with an increase in HIV risk in the CAPRISA 002 trial.<xref rid="aji13542-bib-0018" ref-type="bibr"><sup>18</sup></xref> While this demonstrates that implants have been linked to changes in the genital immune environment, ultimately, we do not understand the mechanisms behind this possible relationship and our findings remain surprising.</p>
              <p>Among women who had high inflammation at baseline, DMPA‐IM and LNG implant were associated with decreases in immune mediators that were not observed in the copper IUD arm. In has been suggested that progestin‐only contraceptives such as DMPA‐IM may have anti‐inflammatory effects by binding to the glucocorticoid receptor.<xref rid="aji13542-bib-0059" ref-type="bibr"><sup>59</sup></xref> It is possible that this causes decreased inflammatory responses among women with high inflammation at baseline. On the other hand, contraceptive induced immunosuppression among individuals with low inflammatory profiles may increase susceptibility to STIs or BV and resulting inflammation. It is also possible that these contraceptives have multiple, divergent effects on immune pathways and the microbiota, dependent on factors that we were not able to assess in this study, and that are important to investigate in future studies.</p>
              <sec id="aji13542-sec-0230">
                <label>4.1</label>
                <title>Limitations</title>
                <p>Sex hormones, particularly oestradiol and progesterone, are also involved in immune regulation in the FGT by maintaining the balance between protection from pathogens while simultaneously allowing for reproductive functions.<xref rid="aji13542-bib-0060" ref-type="bibr"><sup>60</sup></xref> The different levels of endogenous hormones during various menstrual cycle phases may significantly affect FGT inflammation.<xref rid="aji13542-bib-0042" ref-type="bibr"><sup>42</sup></xref>, <xref rid="aji13542-bib-0061" ref-type="bibr"><sup>61</sup></xref>, <xref rid="aji13542-bib-0062" ref-type="bibr"><sup>62</sup></xref>, <xref rid="aji13542-bib-0063" ref-type="bibr"><sup>63</sup></xref>, <xref rid="aji13542-bib-0064" ref-type="bibr"><sup>64</sup></xref> In the future, we will be evaluating baseline levels of and changes in both endogenous and exogenous among the women participating in this study. It will also be useful to explore whether changes in the microbiome may explain immune mediator changes in these women.</p>
                <p>The significantly greater increases in women with low baseline inflammation were accompanied by marginally significant decreases in several immune mediators in women with high baseline inflammation in the DMPA‐IM and LNG implant arm, suggesting the possibility that immune mediator concentrations naturally regressed to a mean value when women were grouped according to their baseline inflammatory profiles. In the copper IUD group, however, no diminution in immune mediator concentrations was observed across the timepoints in women with high baseline inflammation. Additionally, the absolute concentrations of three out of the five significantly raised immune mediators went above their respective baseline means at month 3 following contraceptive initiation (data not shown). Taken together, it is thus unlikely that the changes observed can be attributed to immune mediator levels regressing to a mean level of genital inflammation, particularly in the copper IUD group. Women with high baseline inflammation in the DMPA‐IM and LNG implant group, however, experienced some marginally significant decreases in immune mediators and therefore we cannot disregard the possibility that the differential changes we observed among women with different baseline inflammatory profiles may in part be due to concentrations regressing to the mean.</p>
              </sec>
            </sec>
            <sec id="aji13542-sec-0240">
              <label>5</label>
              <title>CONCLUSION</title>
              <p>The substantial differences in immune mediator changes between women with higher versus lower levels of genital inflammation prior to contraceptive initiation may have contributed to the emergence of contradictory reports on the inflammatory potential of certain contraceptives, particularly for DMPA‐IM. It is, therefore, important to gain a better understanding of the factors that influence immune changes in response to contraceptive use at an individual level to determine the impact of contraceptives on reproductive health, including STI and HIV acquisition risk more broadly. It will also be important to evaluate whether the effects of contraceptives on innate immune mediators are sustained or enhanced over longer periods of time during contraceptive use. Continued research to understand these effects is critical for safe contraceptive use and to inform novel contraceptive development.</p>
            </sec>
            <sec sec-type="COI-statement" id="aji13542-sec-0260">
              <title>CONFLICT OF INTEREST</title>
              <p>There is no competing interest.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="aji13542-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p>Supporting Information</p>
                </caption>
                <media xlink:href="AJI-88-e13542-s001.docx"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="aji13542-sec-0250">
              <title>ACKNOWLEDGEMENTS</title>
              <p>We thank the women who participated in this study for their motivation and dedication and the communities that supported this work and the study teams for the collection, processing, storage, and shipping of the samples. The research reported in this publication was supported by the Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development of the National Institute of Health under Award Number R01HD096937‐01 (PIs: Morrison, Deese and Masson). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. LM was supported by the Carnegie Corporation of New York and South African National Research Foundation (NRF). The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial was supported by the combined generous support of the Bill &amp; Melinda Gates Foundation [grant OPP1032115]; the American people through the United States Agency for International Development [grant AID‐OAA‐A‐15‐00045]; the Swedish International Development Cooperation Agency [grant 2017/762965‐0]; the South Africa Medical Research Council; and the United Nations Population Fund. Contraceptive supplies were donated by the Government of South Africa and US Agency for International Development. The contents of this paper are solely the responsibility of the authors and do not necessarily reflect the views, decisions, or policies of the institutions with which they are affiliated, the ECHO trial funders, or the supporting governments.</p>
            </ack>
            <sec sec-type="data-availability" id="aji13542-sec-0280">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p>
            </sec>
            <ref-list id="aji13542-bibl-0001">
              <title>REFERENCES</title>
              <ref id="aji13542-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0001"><string-name><surname>Kopp Kallner</surname><given-names>H</given-names></string-name>. <article-title>Benefits of reversible contraception</article-title>. <source>F1000Research</source>. <year>2018</year>;<volume>7</volume>:<fpage>1</fpage>‐<lpage>8</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="book" id="aji13542-cit-0002"><collab collab-type="authors">United Nations ‐ Department of Economic and Social Affairs</collab>
. <source>Contraceptive use by Method 2019 ‐ Data Booklet</source>. <publisher-name>United Nations ‐ Department of Economic and Social Affairs</publisher-name>; <year>2019</year>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0003"><string-name><surname>Polis</surname><given-names>CB</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>KM</given-names></string-name>, <string-name><surname>Hannaford</surname><given-names>PC</given-names></string-name>, et al. <article-title>An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women</article-title>. <source>Aids</source>. <year>2016</year>;<volume>30</volume>:<fpage>2665</fpage>‐<lpage>2683</lpage>.<pub-id pub-id-type="pmid">27500670</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0004"><string-name><surname>Morrison</surname><given-names>CS</given-names></string-name>, <string-name><surname>Chen</surname><given-names>PL</given-names></string-name>, <string-name><surname>Kwok</surname><given-names>C</given-names></string-name>, et al. <article-title>Hormonal contraception and the risk of HIV acquisition: an individual participant data meta‐analysis</article-title>. <source>PLoS Med</source>. <year>2015</year>;<volume>12</volume>:<fpage>1</fpage>‐<lpage>26</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0005"><string-name><surname>Polis</surname><given-names>CB</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>KM</given-names></string-name>, <string-name><surname>Hannaford</surname><given-names>PC</given-names></string-name>, et al. <article-title>Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence</article-title>. <source>Contraception</source>. <year>2014</year>;<volume>90</volume>:<fpage>360</fpage>‐<lpage>390</lpage>.<pub-id pub-id-type="pmid">25183264</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0006"><string-name><surname>Ahmed</surname><given-names>K</given-names></string-name>, <collab collab-type="authors">Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium</collab>
. <article-title>HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open‐label trial</article-title>. <source>Lancet</source>. <year>2019</year>;<volume>27</volume>:<fpage>1</fpage>‐<lpage>11</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0007"><string-name><surname>Hapgood</surname><given-names>JP</given-names></string-name>. <article-title>Is the injectable contraceptive Depo‐Medroxyprogesterone Acetate (DMPA‐IM) associated with an increased risk for HIV acquisition? The jury is still out</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2020</year>;<volume>00</volume>:<fpage>1</fpage>‐<lpage>10</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0008"><string-name><surname>Masson</surname><given-names>L</given-names></string-name>, <string-name><surname>Passmore</surname><given-names>J‐NS</given-names></string-name>, <string-name><surname>Liebenberg</surname><given-names>LJ</given-names></string-name>, et al. <article-title>Genital inflammation and the risk of HIV acquisition in women</article-title>. <source>Clin Infect Dis</source>. <year>2015</year>;<volume>61</volume>:<fpage>260</fpage>‐<lpage>269</lpage>.<pub-id pub-id-type="pmid">25900168</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0009"><string-name><surname>Wiesenfeld</surname><given-names>HC</given-names></string-name>, <string-name><surname>Hillier</surname><given-names>SL</given-names></string-name>, <string-name><surname>Meyn</surname><given-names>LA</given-names></string-name>, <string-name><surname>Amortegui</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Sweet</surname><given-names>RL</given-names></string-name>. <article-title>Subclinical pelvic inflammatory disease and infertility</article-title>. <source>Obstet Gynecol</source>. <year>2012</year>;<volume>120</volume>:<fpage>37</fpage>‐<lpage>43</lpage>.<pub-id pub-id-type="pmid">22678036</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0010"><string-name><surname>Lin</surname><given-names>WC</given-names></string-name>, <string-name><surname>Chang</surname><given-names>CYY</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>YA</given-names></string-name>, <string-name><surname>Chiang</surname><given-names>JH</given-names></string-name>, <string-name><surname>Wan</surname><given-names>L</given-names></string-name>. <article-title>Increased risk of endometriosis in patients with lower genital tract infection: a nationwide cohort study</article-title>. <source>Medicine (United States)</source>. <year>2016</year>;<volume>95</volume>:<fpage>1</fpage>‐<lpage>8</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0011"><string-name><surname>Cram</surname><given-names>LF</given-names></string-name>, <string-name><surname>Zapata</surname><given-names>MI</given-names></string-name>, <string-name><surname>Toy</surname><given-names>EC</given-names></string-name>, <string-name><surname>Baker</surname><given-names>B</given-names></string-name>. <article-title>Genitourinary infections and their association with preterm labor</article-title>. <source>Am Fam Physician</source>. <year>2002</year>;<volume>65</volume>:<fpage>241</fpage>‐<lpage>248</lpage>.<pub-id pub-id-type="pmid">11820488</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0012"><string-name><surname>Ngcapu</surname><given-names>S</given-names></string-name>, <string-name><surname>Masson</surname><given-names>L</given-names></string-name>, <string-name><surname>Sibeko</surname><given-names>S</given-names></string-name>, et al. <article-title>Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with use of injectable hormonal contraceptive</article-title>. <source>J Reprod Immunol</source>. <year>2015</year>;<volume>110</volume>:<fpage>14</fpage>‐<lpage>21</lpage>.<pub-id pub-id-type="pmid">25956139</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0013"><string-name><surname>Quispe Calla</surname><given-names>NE</given-names></string-name>, <string-name><surname>Miguel</surname><given-names>RDV</given-names></string-name>, <string-name><surname>Boyaka</surname><given-names>PN</given-names></string-name>, et al. <article-title>Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection</article-title>. <source>Mucosal Immunol</source>. <year>2016</year>;<volume>118</volume>, <fpage>6072</fpage>‐<lpage>6078</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0014"><string-name><surname>Morrison</surname><given-names>C</given-names></string-name>, <string-name><surname>Fichorova</surname><given-names>RN</given-names></string-name>, <string-name><surname>Mauck</surname><given-names>C</given-names></string-name>, et al. <article-title>Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV‐1 seroconversion</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2014</year>;<volume>66</volume>:<fpage>109</fpage>‐<lpage>117</lpage>.<pub-id pub-id-type="pmid">24413042</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0015"><string-name><surname>Achilles</surname><given-names>SL</given-names></string-name>, <string-name><surname>Austin</surname><given-names>MN</given-names></string-name>, <string-name><surname>Meyn</surname><given-names>LA</given-names></string-name>, et al. <article-title>Impact of contraceptive initiation on vaginal microbiota</article-title>. <source>Am J Obstet Gynecol</source>. <year>2018</year>;<volume>218</volume>:<fpage>622.e1</fpage>‐<lpage>622.e10</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0016"><string-name><surname>Masson</surname><given-names>L</given-names></string-name>, <string-name><surname>Mlisana</surname><given-names>K</given-names></string-name>, <string-name><surname>Little</surname><given-names>F</given-names></string-name>, et al. <article-title>Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross‐sectional study</article-title>. <source>Sex Transm Infect</source>. <year>2014</year>;<volume>90</volume>:<fpage>580</fpage>‐<lpage>587</lpage>.<pub-id pub-id-type="pmid">25107710</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="miscellaneous" id="aji13542-cit-0017"><string-name><surname>Noel‐Romas</surname><given-names>L</given-names></string-name>, <string-name><surname>Perner</surname><given-names>M</given-names></string-name>, <string-name><surname>Molatlhegi</surname><given-names>R</given-names></string-name>, et al. <article-title>HIV acquisition risk and genital inflammation associated with hormonal contraceptives is dependent on the vaginal microbiome</article-title>. <year>2019</year>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0018"><string-name><surname>Mlisana</surname><given-names>K</given-names></string-name>, <string-name><surname>Naicker</surname><given-names>N</given-names></string-name>, <string-name><surname>Werner</surname><given-names>L</given-names></string-name>, et al. <article-title>Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high‐risk women in South Africa</article-title>. <source>J Infect Dis</source>. <year>2012</year>;<volume>206</volume>:<fpage>6</fpage>‐<lpage>14</lpage>.<pub-id pub-id-type="pmid">22517910</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0019"><string-name><surname>Deese</surname><given-names>J</given-names></string-name>, <string-name><surname>Masson</surname><given-names>L</given-names></string-name>, <string-name><surname>Miller</surname><given-names>W</given-names></string-name>, et al. <article-title>Injectable progestin‐only contraception is associated with increased levels of pro‐inflammatory cytokines in the female genital tract</article-title>. <source>Am J Reprod Immunol</source>. <year>2015</year>;<volume>74</volume>:<fpage>357</fpage>‐<lpage>367</lpage>.<pub-id pub-id-type="pmid">26202107</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0020"><string-name><surname>Schirm</surname><given-names>J</given-names></string-name>, <string-name><surname>Bos</surname>, <given-names>PAJ</given-names></string-name>, <string-name><surname>Roozeboom‐Roelfsema</surname><given-names>IK</given-names></string-name>, <string-name><surname>Luijt</surname><given-names>DS</given-names></string-name>, <string-name><surname>Möller</surname><given-names>LV</given-names></string-name>. <article-title>Trichomonas vaginalis detection using real‐time TaqMan PCR</article-title>. <source>J Microbiol Methods</source>. <year>2007</year>;<volume>68</volume>:<fpage>243</fpage>‐<lpage>247</lpage>.<pub-id pub-id-type="pmid">17005275</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0021"><string-name><surname>Columb</surname><given-names>MO</given-names></string-name>, <string-name><surname>Sagadai</surname><given-names>S</given-names></string-name>. <article-title>Multiple comparisons</article-title>. <source>Curr. Anaesth Crit Care</source>. <year>2006</year>;<volume>17</volume>:<fpage>233</fpage>‐<lpage>236</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0022"><string-name><surname>Dabee</surname><given-names>S</given-names></string-name>, <string-name><surname>Barnabas</surname><given-names>SL</given-names></string-name>, <string-name><surname>Lennard</surname><given-names>KS</given-names></string-name>, et al. <article-title>Defining characteristics of genital health in South African adolescent girls and young women at high risk for HIV infection</article-title>. <source>PLoS One</source>. <year>2019</year>;<volume>14</volume>:<fpage>1</fpage>‐<lpage>20</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0023"><string-name><surname>Byrne</surname><given-names>EH</given-names></string-name>, <string-name><surname>Anahtar</surname><given-names>MN</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>KE</given-names></string-name>, et al. <article-title>Association between injectable progestin‐only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study</article-title>. <source>Lancet Infect Dis</source>. <year>2016</year>;<volume>16</volume>:<fpage>441</fpage>‐<lpage>448</lpage>.<pub-id pub-id-type="pmid">26723758</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0024"><string-name><surname>Arnold</surname><given-names>KB</given-names></string-name>, <string-name><surname>Burgener</surname><given-names>A</given-names></string-name>, <string-name><surname>Birse</surname><given-names>K</given-names></string-name>, et al. <article-title>Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV‐susceptible target cells</article-title>. <source>Mucosal Immunol</source>. <year>2016</year>;<volume>9</volume>:<fpage>194</fpage>‐<lpage>205</lpage>.<pub-id pub-id-type="pmid">26104913</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0025"><string-name><surname>Nkwanyana</surname><given-names>NN</given-names></string-name>, <string-name><surname>Gumbi</surname><given-names>PP</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>L</given-names></string-name>, et al. <article-title>Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract</article-title>. <source>Immunology</source>. <year>2009</year>;<volume>128</volume>:<fpage>e746</fpage>‐<lpage>e757</lpage>.<pub-id pub-id-type="pmid">19740336</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0026"><string-name><surname>Osborn</surname><given-names>L</given-names></string-name>, <string-name><surname>Kunkel</surname><given-names>S</given-names></string-name>, <string-name><surname>Nabel</surname><given-names>GJ</given-names></string-name>. <article-title>Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1989</year>;<volume>86</volume>:<fpage>2336</fpage>‐<lpage>2240</lpage>.<pub-id pub-id-type="pmid">2494664</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0027"><string-name><surname>Omollo</surname><given-names>K</given-names></string-name>, <string-name><surname>Lajoie</surname><given-names>J</given-names></string-name>, <string-name><surname>Oyugi</surname><given-names>J</given-names></string-name>, et al. <article-title>Differential elevation of inflammation and CD4+ T cell activation in Kenyan female sex workers and non‐sex workers using depot‐medroxyprogeterone acetate</article-title>. <source>Front Immunol</source>. <year>2020</year>;<volume>11</volume>:<fpage>3936</fpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0028"><string-name><surname>Anahtar</surname><given-names>MN</given-names></string-name>, <string-name><surname>Byrne</surname><given-names>EH</given-names></string-name>, <string-name><surname>Doherty</surname><given-names>KE</given-names></string-name>, et al. <article-title>Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract</article-title>. <source>Immunity</source>. <year>2016</year>;<volume>42</volume>:<fpage>965</fpage>‐<lpage>976</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0029"><string-name><surname>Lennard</surname><given-names>K</given-names></string-name>, et al. <article-title>Vaginal microbiota varies by geographical location in south African women</article-title>. <source>Suid‐ Afrikaanse Tydskr vir Natuurwetenskap en Tegnol South Africa</source>. <year>2019</year>;<volume>38</volume>:<fpage>1</fpage>‐<lpage>9</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0030"><string-name><surname>Gosmann</surname><given-names>C</given-names></string-name>, <string-name><surname>Anahtar</surname><given-names>MN</given-names></string-name>, <string-name><surname>Handley</surname><given-names>SA</given-names></string-name>, et al. <article-title>Lactobacillus‐deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African Women</article-title>. <source>Immunity</source>. <year>2018</year>;<volume>46</volume>:<fpage>29</fpage>‐<lpage>37</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0031"><string-name><surname>Masson</surname><given-names>L</given-names></string-name>, <string-name><surname>Barnabas</surname><given-names>S</given-names></string-name>, <string-name><surname>Deese</surname><given-names>J</given-names></string-name>, et al. <article-title>Inflammatory cytokine biomarkers of asymptomatic sexually transmitted infections and vaginal dysbiosis: a multicentre validation study</article-title>. <source>Sex Transm Infect</source>. <year>2019</year>;<volume>95</volume>:<fpage>5</fpage>‐<lpage>12</lpage>.<pub-id pub-id-type="pmid">30018088</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0032"><string-name><surname>Lennard</surname><given-names>K</given-names></string-name>, <string-name><surname>Dabee</surname><given-names>S</given-names></string-name>, <string-name><surname>Barnabas</surname><given-names>SL</given-names></string-name>, et al. <article-title>Microbial composition predicts genital tract inflammation and persistent bacterial vaginosis in South African adolescent females</article-title>. <source>Infect Immun</source>. <year>2018</year>;<volume>86</volume>:<fpage>e00410</fpage>‐<lpage>e00417</lpage>.<pub-id pub-id-type="pmid">29038128</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0033"><string-name><surname>Thurman</surname><given-names>TR</given-names></string-name>, <string-name><surname>Nice</surname><given-names>J</given-names></string-name>, <string-name><surname>Visser</surname><given-names>M</given-names></string-name>, <string-name><surname>Luckett</surname><given-names>BG</given-names></string-name>. <article-title>Social Science &amp; Medicine Pathways to sexual health communication between adolescent girls and their female caregivers participating in a structured HIV prevention intervention in South Africa</article-title>. <source>Soc Sci Med</source>. <year>2020</year>;<volume>260</volume>:<elocation-id>113168</elocation-id>.<pub-id pub-id-type="pmid">32717662</pub-id></mixed-citation>
              </ref>
              <ref id="aji13542-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0034"><string-name><surname>Low</surname><given-names>N</given-names></string-name>, <string-name><surname>Chersich</surname><given-names>MF</given-names></string-name>, <string-name><surname>Schmidlin</surname><given-names>K</given-names></string-name>, et al. <article-title>Intravaginal practices, bacterial vaginosis, and HIV infection in women: Individual participant data meta‐analysis</article-title>. <source>PLoS Med</source>. <year>2011</year>;<volume>8</volume>:<fpage>1</fpage>‐<lpage>14</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0035"><string-name><surname>Brotman</surname><given-names>RM</given-names></string-name>, <string-name><surname>He</surname><given-names>X</given-names></string-name>, <string-name><surname>Gajer</surname><given-names>P</given-names></string-name>, et al. <article-title>Association between cigarette smoking and the vaginal microbiota: a pilot study</article-title>. <source>BMC Infect Dis</source>. <year>2014</year>;<volume>14</volume>:<fpage>1</fpage>‐<lpage>11</lpage>.<pub-id pub-id-type="pmid">24380631</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0036"><string-name><surname>Akoh</surname><given-names>CC</given-names></string-name>, <string-name><surname>Pressman</surname><given-names>EK</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>E</given-names></string-name>, et al. <article-title>Low vitamin D is associated with infections and proinflammatory cytokines during pregnancy</article-title>. <source>Reprod Sci</source>. <year>2018</year>;<volume>25</volume>:<fpage>414</fpage>‐<lpage>423</lpage>.<pub-id pub-id-type="pmid">28618852</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0037"><string-name><surname>Darville</surname><given-names>T</given-names></string-name>, <string-name><surname>O'Neill</surname><given-names>JM</given-names></string-name>, <string-name><surname>Andrews</surname><given-names>CW</given-names>, <suffix>Jr.</suffix></string-name>, et al. <article-title>Toll‐like receptor‐2, but not toll‐like receptor‐4, is essential for development of oviduct pathology in chlamydial genital tract infection</article-title>. <source>J Immunol</source>. <year>2003</year>;<volume>171</volume>:<fpage>6187</fpage>‐<lpage>6197</lpage>.<pub-id pub-id-type="pmid">14634135</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0038"><string-name><surname>Aflatoonian</surname><given-names>R</given-names></string-name>, <string-name><surname>Tuckerman</surname><given-names>E</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>SL</given-names></string-name>, et al. <article-title>Menstrual cycle‐dependent changes of Toll‐like receptors in endometrium</article-title>. <source>Hum Reprod</source>. <year>2007</year>;<volume>22</volume>:<fpage>586</fpage>‐<lpage>593</lpage>.<pub-id pub-id-type="pmid">17043100</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0039"><string-name><surname>Lin</surname><given-names>Z</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name><surname>Jin</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name><surname>Ge</surname><given-names>F</given-names></string-name>. <article-title>Modulation of expression of toll‐like receptors in the human endometrium</article-title>. <source>Am J Reprod Immunol</source>. <year>2009</year>;<volume>61</volume>:<fpage>338</fpage>‐<lpage>345</lpage>.<pub-id pub-id-type="pmid">19341384</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0040"><string-name><surname>Genc</surname><given-names>MR</given-names></string-name>, <string-name><surname>Vardhana</surname><given-names>S</given-names></string-name>, <string-name><surname>Delaney</surname><given-names>ML</given-names></string-name>, et al. <article-title>Relationship between a toll‐like receptor‐4 gene polymorphism, bacterial vaginosis‐related flora and vaginal cytokine responses in pregnant women</article-title>. <source>Eur J Obstet Gynecol Reprod Biol</source>. <year>2004</year>;<volume>116</volume>:<fpage>152</fpage>‐<lpage>156</lpage>.<pub-id pub-id-type="pmid">15358455</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0041"><string-name><surname>Genç</surname><given-names>MR</given-names></string-name>, <string-name><surname>Vardhana</surname><given-names>S</given-names></string-name>, <string-name><surname>Delaney</surname><given-names>ML</given-names></string-name>, <string-name><surname>Witkin</surname><given-names>SS</given-names></string-name>, <string-name><surname>Onderdonk</surname><given-names>AB</given-names></string-name>. <article-title>TNFA‐308G&gt;A polymorphism influences the TNF‐α response to altered vaginal flora</article-title>. <source>Eur J Obstet Gynecol Reprod Biol</source>. <year>2007</year>;<volume>134</volume>:<fpage>188</fpage>‐<lpage>191</lpage>.<pub-id pub-id-type="pmid">17123692</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0042"><string-name><surname>Vitali</surname><given-names>D</given-names></string-name>, <string-name><surname>Wessels</surname><given-names>JM</given-names></string-name>, <string-name><surname>Kaushic</surname><given-names>C</given-names></string-name>. <article-title>Role of sex hormones and the vaginal microbiome in susceptibility and mucosal immunity to HIV‐1 in the female genital tract</article-title>. <source>AIDS Res Ther</source>. <year>2017</year>;<volume>14</volume>:<fpage>1</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">28086929</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0043"><string-name><surname>Farage</surname><given-names>M</given-names></string-name>, <string-name><surname>Maibach</surname><given-names>H</given-names></string-name>. <article-title>Lifetime changes in the vulva and vagina</article-title>. <source>Arch Gynecol Obstet</source>. <year>2006</year>;<volume>273</volume>:<fpage>195</fpage>‐<lpage>202</lpage>.<pub-id pub-id-type="pmid">16208476</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0044"><string-name><surname>Matubu</surname><given-names>AT</given-names></string-name>, <string-name><surname>Hillier</surname><given-names>SL</given-names></string-name>, <string-name><surname>Meyn</surname><given-names>LA</given-names></string-name>, et al. <article-title>Effect of injectable progestin‐ only contraceptives, depot medroxyprogesterone acetate and norethisterone enanthate, on cytokine production during T‐cell activation</article-title>. <source>Am J Reprod Immunol</source>. <year>2021</year>;<volume>86</volume>(<issue>1</issue>):<elocation-id>e13405</elocation-id>.<pub-id pub-id-type="pmid">33609312</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0045"><string-name><surname>Brooks</surname><given-names>JP</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Blithe</surname><given-names>DL</given-names></string-name>, et al. <article-title>Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel‐releasing intrauterine system on the vaginal microbiome</article-title>. <source>Contraception</source>. <year>2017</year>;<volume>95</volume>:<fpage>405</fpage>‐<lpage>413</lpage>.<pub-id pub-id-type="pmid">27913230</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0046"><string-name><surname>Onywera</surname><given-names>H</given-names></string-name>, <string-name><surname>Williamson</surname><given-names>AL</given-names></string-name>, <string-name><surname>Mbulawa</surname><given-names>ZZA</given-names></string-name>, <string-name><surname>Coetzee</surname><given-names>D</given-names></string-name>, <string-name><surname>Meiring</surname><given-names>TL</given-names></string-name>. <article-title>The cervical microbiota in reproductive‐age South African women with and without human papillomavirus infection</article-title>. <source>Papillomavirus Res</source>. <year>2019</year>;<volume>7</volume>:<fpage>154</fpage>‐<lpage>163</lpage>.<pub-id pub-id-type="pmid">30986570</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0047"><string-name><surname>Wessels</surname><given-names>JM</given-names></string-name>, <string-name><surname>Lajoie</surname><given-names>J</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>MIJH</given-names></string-name>, et al. <article-title>Medroxyprogesterone acetate alters the vaginal microbiota and microenvironment in a Kenyan sex worker cohort and is also associated with increased susceptibility to HIV‐1 in humanized mice</article-title>. <source>Dis Model Mech</source>. <year>2019</year>;<volume>12</volume>:<elocation-id>dmm039669</elocation-id>.<pub-id pub-id-type="pmid">31537512</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0048"><string-name><surname>Whitney</surname><given-names>BM</given-names></string-name>, <string-name><surname>Guthrie</surname><given-names>BL</given-names></string-name>, <string-name><surname>Srinivasan</surname><given-names>S</given-names></string-name>, et al. <article-title>Changes in key vaginal bacteria among postpartum African women initiating intramuscular depot‐medroxyprogesterone acetate</article-title>. <source>PLoS One</source>. <year>2020</year>;<volume>15</volume>:<fpage>1</fpage>‐<lpage>19</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0049"><string-name><surname>Van De Wijgert</surname><given-names>JHHM</given-names></string-name>, <string-name><surname>Verwijs</surname><given-names>MC</given-names></string-name>, <string-name><surname>Turner</surname><given-names>AN</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>CS</given-names></string-name>. <article-title>Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: Implications for HIV transmission</article-title>. <source>Aids</source>. <year>2013</year>;<volume>27</volume>:<fpage>2141</fpage>‐<lpage>2153</lpage>.<pub-id pub-id-type="pmid">23660575</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0050">
                <label>50</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0050"><string-name><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name><surname>Hao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Hu</surname><given-names>J</given-names></string-name>, et al. <article-title>Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women</article-title>. <source>Emerg. Microbes Infect</source>. <year>2019</year>;<volume>8</volume>:<fpage>197</fpage>‐<lpage>210</lpage>.<pub-id pub-id-type="pmid">30866773</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0051">
                <label>51</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0051"><string-name><surname>Madden</surname><given-names>T</given-names></string-name>, <string-name><surname>Grentzer</surname><given-names>JM</given-names></string-name>, <string-name><surname>Secura</surname><given-names>GM</given-names></string-name>, <string-name><surname>Allsworth</surname><given-names>JE</given-names></string-name>, <string-name><surname>Peipert</surname><given-names>JF</given-names></string-name>. <article-title>Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study</article-title>. <source>Sex Transm Dis</source>. <year>2012</year>;<volume>39</volume>:<fpage>217</fpage>‐<lpage>222</lpage>.<pub-id pub-id-type="pmid">22337109</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0052">
                <label>52</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0052"><string-name><surname>Elhag</surname><given-names>KM</given-names></string-name>, <string-name><surname>Bahar</surname><given-names>AM</given-names></string-name>, <string-name><surname>Mubarak</surname><given-names>AA</given-names></string-name>. <article-title>The effect of a copper intra‐uterine contraceptive device on the microbial ecology of the female genital tract</article-title>. <source>J Med Microbiol</source>. <year>1988</year>;<volume>25</volume>:<fpage>245</fpage>‐<lpage>251</lpage>.<pub-id pub-id-type="pmid">3357191</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0053">
                <label>53</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0053"><string-name><surname>Hubacher</surname><given-names>D</given-names></string-name>, <string-name><surname>Chen</surname><given-names>P‐L</given-names></string-name>, <string-name><surname>Park</surname><given-names>S</given-names></string-name>. <article-title>Side effects from the copper IUD: do they decrease over time?</article-title><source>Contraception</source>. <year>2009</year>;<volume>79</volume>:<fpage>356</fpage>‐<lpage>362</lpage>.<pub-id pub-id-type="pmid">19341847</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0054">
                <label>54</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0054"><string-name><surname>Sanders</surname><given-names>JN</given-names></string-name>, <string-name><surname>Adkins</surname><given-names>DE</given-names></string-name>, <string-name><surname>Kaur</surname><given-names>S</given-names></string-name>, <string-name><surname>Storck</surname><given-names>K</given-names></string-name>, <string-name><surname>Gawron</surname><given-names>LM</given-names></string-name>. <article-title>Bleeding, cramping, and satisfaction among new copper IUD users: a prospective study</article-title>. <source>PLoS One</source>. <year>2018</year>;<volume>13</volume>:<fpage>1</fpage>‐<lpage>11</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0055">
                <label>55</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0055"><string-name><surname>Srinivasan</surname><given-names>S</given-names></string-name>, <string-name><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>CM</given-names></string-name>, et al. <article-title>Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis</article-title>. <source>PLoS One</source>. <year>2010</year>;<volume>5</volume>:<elocation-id>e10197</elocation-id>.<pub-id pub-id-type="pmid">20419168</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0056">
                <label>56</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0056"><string-name><surname>Peebles</surname><given-names>K</given-names></string-name>, <string-name><surname>Kiweewa</surname><given-names>FM</given-names></string-name>, <string-name><surname>Palanee‐Phillips</surname><given-names>T</given-names></string-name>, et al. <article-title>Elevated risk of bacterial vaginosis among users of the copper intrauterine device: a Prospective Longitudinal Cohort Study</article-title>. <source>Clin Infect Dis</source>. <year>2020</year>;<volume>98195</volume>:<fpage>1</fpage>‐<lpage>8</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0057">
                <label>57</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0057"><string-name><surname>Achilles</surname><given-names>SL</given-names></string-name>, <string-name><surname>Meyn</surname><given-names>LA</given-names></string-name>, <string-name><surname>Mhlanga</surname><given-names>FG</given-names></string-name>, et al. <article-title>Zim CHIC: a cohort study of immune changes in the female genital tract associated with initiation and use of contraceptives</article-title>. <source>Am J Reprod Immunol</source>. <year>2020</year>;<volume>84</volume>:<fpage>1</fpage>‐<lpage>13</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0058">
                <label>58</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0058"><string-name><surname>Haddad</surname><given-names>LB</given-names></string-name>, <string-name><surname>Swaims‐Kohlmeier</surname><given-names>A</given-names></string-name>, <string-name><surname>Mehta</surname><given-names>CC</given-names></string-name>, et al. <article-title>Impact of etonogestrel implant use on T‐cell and cytokine profiles in the female genital tract and blood</article-title>. <source>PLoS One</source>. <year>2020</year>;<volume>15</volume>:<fpage>1</fpage>‐<lpage>18</lpage>.</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0059">
                <label>59</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0059"><string-name><surname>Hapgood</surname><given-names>JP</given-names></string-name>, <string-name><surname>Kaushic</surname><given-names>C</given-names></string-name>, <string-name><surname>Hel</surname><given-names>Z</given-names></string-name>. <article-title>Hormonal contraception and HIV‐1 acquisition: biological mechanisms</article-title>. <source>Endocr Rev</source>. <year>2018</year>:<fpage>36</fpage>‐<lpage>78</lpage>.<pub-id pub-id-type="pmid">29309550</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0060">
                <label>60</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0060"><string-name><surname>Wessels</surname><given-names>JM</given-names></string-name>, <string-name><surname>Felker</surname><given-names>AM</given-names></string-name>, <string-name><surname>Dupont</surname><given-names>HA</given-names></string-name>, <string-name><surname>Kaushic</surname><given-names>C</given-names></string-name>. <article-title>The relationship between sex hormones, the vaginal microbiome and immunity in HIV‐1 susceptibility in women</article-title>. <source>Dis Model Mech</source>. <year>2018</year>;<volume>11</volume>:<elocation-id>dmm035147</elocation-id>.<pub-id pub-id-type="pmid">30154116</pub-id></mixed-citation>
              </ref>
              <ref id="aji13542-bib-0061">
                <label>61</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0061"><string-name><surname>Dunbar</surname><given-names>B</given-names></string-name>, <string-name><surname>Patel</surname><given-names>M</given-names></string-name>, <string-name><surname>Fahey</surname><given-names>J</given-names></string-name>, <string-name><surname>Wira</surname><given-names>C</given-names></string-name>. <article-title>Endocrine control of mucosal immunity in the female reproductive tract: impact of environmental disruptors</article-title>. <source>Mol Cell Endocrinol</source>. <year>2012</year>;<volume>354</volume>:<fpage>85</fpage>‐<lpage>93</lpage>.<pub-id pub-id-type="pmid">22289638</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0062">
                <label>62</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0062"><string-name><surname>Kaushic</surname><given-names>C</given-names></string-name>, <string-name><surname>Roth</surname><given-names>KL</given-names></string-name>, <string-name><surname>Anipindi</surname><given-names>V</given-names></string-name>, <string-name><surname>Xiu</surname><given-names>F</given-names></string-name>. <article-title>Increased prevalence of sexually transmitted viral infections in women: the role of female sex hormones in regulating susceptibility and immune responses</article-title>. <source>J Reprod Immunol</source>. <year>2011</year>;<volume>88</volume>:<fpage>204</fpage>‐<lpage>209</lpage>.<pub-id pub-id-type="pmid">21296427</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0063">
                <label>63</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0063"><string-name><surname>Nguyen</surname><given-names>PV</given-names></string-name>, <string-name><surname>Kafka</surname><given-names>JK</given-names></string-name>, <string-name><surname>Ferreira</surname><given-names>VH</given-names></string-name>, <string-name><surname>Roth</surname><given-names>K</given-names></string-name>, <string-name><surname>Kaushic</surname><given-names>C</given-names></string-name>. <article-title>Innate and adaptive immune responses in male and female reproductive tracts in homeostasis and following HIV infection</article-title>. <source>Cell Mol Immunol</source>. <year>2014</year>;<volume>11</volume>:<fpage>410</fpage>‐<lpage>427</lpage>.<pub-id pub-id-type="pmid">24976268</pub-id>
</mixed-citation>
              </ref>
              <ref id="aji13542-bib-0064">
                <label>64</label>
                <mixed-citation publication-type="journal" id="aji13542-cit-0064"><string-name><surname>Wira</surname><given-names>CR</given-names></string-name>, <string-name><surname>Rodriguez‐Garcia</surname><given-names>M</given-names></string-name>, <string-name><surname>Patel</surname><given-names>MV</given-names></string-name>. <article-title>The role of sex hormones in immune protection of the female reproductive tract</article-title>. <source>Nat Rev Immunol</source>. <year>2015</year>;<volume>15</volume>:<fpage>217</fpage>‐<lpage>230</lpage>.<pub-id pub-id-type="pmid">25743222</pub-id>
</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
